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1. Abbreviations 
8-OHdG 8-hydroxy-2-deoxyguanosine 
AR  autoradiography 
Bax  Bcl-2-associated x protein 
Bcl-2  B-cell lymphoma-2 
Bcl-xl  B-cell lymphoma XL 
BH2  Bcl-2 homology 2 
BIP   binding protein   
BME  2-mercaptoethanol 
bp  basepair 
BSA  bovine serum albumine 
C1  proteolytic fragment of PrPC 
CHO-K1 Chinese hamster ovary cells 
CMV  cytomegalo virus 
CNS  central nervous system 
CO2  carbon dioxide 
CtmPrP  C-terminal transmembrane PrP (Type II) 
DAB  diamino benzidine 
DNA  deoxyribonucleic acid 
Dox  doxycyline 
DTT   dithiothreitol 
EDTA  ethylene-diamine-tetra-acetic acid 
Endo H endoglycosidase H 
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ER  endoplasmatic reticulum 
ERAD  ER-associated degradation 
FBS  fetal bovine serum 
GAPDH glyceraldehyde 3-phosphate dehydrogenase 
GCL  granule cell layer 
GCN  granule cell neurons 
GPI  glycosylphosphatidyl inositol 
GRP94 glucose response protein 94 kD 
H2O  water           
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP  horseradish peroxidase 
ICC  immunocytochemistry 
IgG  immunoglobulin G 
IHC  immunohistochemistry  
IP  immunoprecipitation 
KA  kainic acid 
kD  kilo Dalton 
KH®II SHaPrP, K110I, H111I 
mAb   monoclonal antibody 
MDA  malondialdehyde 
mPrP  mouse PrP 
NGS  normal goat serum 
NtmPrP  N-terminal transmembrane PrP (Type I) 
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OR  octarepeat 
P  postnatal 
PAGE  polyacrylamide gel-electrophoresis 
PBS  phosphate-buffered saline 
PBST  PBS with Tween-20 
PCR  polymerase chain reaction 
PI  propidium iodide 
PK  proteinase K 
PMSF  phenylmethylsulfonyl fluoride 
Prnp  PrP gene 
Prnp-/-  PrP knockout mice 
PrP  prion protein 
PrPC  cellular prion protein 
PrPSc  disease causing PrP 
ROS  reactive oxygen species 
RT  room temperature     
SDS  sodium dodecyl sulfate 
SecPrP  secretory PrP 
SHaPrP Syrian hamster PrP 
SRP  signal recognition particle 
SS  signal sequence 
STE  stop transfer effector 
TCA  tri-chlor-acetate 
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Tg  transgenic 
TM  transmembrane 
TRAM  translocation chain-associated membrane protein 
TRAP  tranlocon-associated protein 
TRE  tetracycline response element 
TRIS   tris-(hydroxymethyl)-aminomethane 
tTA  tetracycline transactivator 
TUNEL terminal UDP-mediated nick end labeling 
UPS  ubiquitin proteasome system 
v/v  volume/ volume 
w/v  weight/ volume 
wt  wild type 
DSTE  SHaPrP, D104-113
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2. Introduction 
Prions came to prominence for their involvement in transmissible 
neurodegenerative disorders including scrapie in sheep and Creutzfeld -Jacob 
Disease and Kuru in humans (Prusiner, 1998). Interest was further heightened by 
the development of bovine spongiform encephalitis (BSE) in the United Kingdom 
which was caused by prion–contaminated bone meal (Kimberlin, 1991; Wilesmith 
et al., 1991). Prions are proteinaceous infectious particles that are devoid of 
nucleic acids (Kellings et al., 1992; Kellings et al., 1994; Safar et al., 2005) yet 
retain and transfer biological information in form of conformation in a non-
mendelian fashion causing fatal neurodegenerative disease in mammals. Prion 
diseases may have an infectious, genetic or sporadic etiology (Prusiner, 1998) 
that result from changes in the conformation of the normal cellular prion protein 
(PrPC; Weissmann, 2004). Great progress has been made in understanding the 
basis for prion infectivity and conversion to the pathogenic conformation 
(Prusiner et al., 1998), however very little is understood about the mechanisms 
that underlie the pathogenesis process. 
 
2.1 Distinctive roles for PrPSc and PrPC in prion disease 
Upon infection with the disease-causing isoform termed PrPSc, host encoded 
PrPC which is expressed at high levels in the central nervous system (CNS; 
Kretzschmar et al., 1986) is converted to PrPSc which in turn stimulates 
conversion of further PrP C molecules leading to the accumulation of PrPSc in the 
CNS (Figure 1; Prusiner, 1998). Two key biochemical properties of prions appear 
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to be crucial for the manifestation of its infectious nature:  First, the extreme 
conformational stability of PrPSc makes it highly resistant to chemical, heat or 
enzymatic degradation thereby facilitating PrPSc accumulation (Riesner, 2003). 
 
The methods established for the detection of PrPSc and the discrimination from 
PrPC exploit this conformational stability as PrPSc withstands harsh proteolysis 
(Caughey et al., 1990) and formic acid treatment (Kitamoto et al., 1987). Second, 






Legend Figure 1. PrPC is required for the conversion and infectivity of prions. Upon 
infection with the disease causing isoform (PrPSc) and proximity with the cellular isoform of the 
prion protein (PrPC) conversion of PrPC to PrPSc occurs by a yet unknown mechanism, which 
can convert more PrPC molecules to PrPSc, trigger disease and propagate further infectivity. In 
contrast PrP knockout mice (Prnp-/-) show no signs of PrPSc accumulation, do not develop 
disease and do not spread infectivity (Prusiner, 1998). Therefore toxicity appears to be 
mediated by PrPC. 
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ensures that once even a few PrPSc molecules reach the host CNS, disease can 
unfold (Prusiner, 1998). The rate of PrPSc accumulation and the onset of disease 
depends on various factors such as host PrPC expression level (Bueler et al., 
1994),  titer of PrPSc inoculum (De Armond et al., 1989), species of host and 
donor PrP (Bruce et al., 1994), variants of PrPSc known as strains (Aguzzi et al., 
2007) and other less well understood genetic factors (Carlson et al., 1986; 
Westaway et al., 1987).    
Despite the overwhelming evidence in support for the central role of PrPSc in the 
infectivity process of prion diseases, evidence suggests that PrPSc does not itself 
cause disease directly. Host encoded PrPC is required for the pathogenesis 
process as evidenced in PrP knockout mice (Prnp-/-) which are immune to 
infection with PrPSc (Bueler et al., 1993; Sailer et al., 1994). Transplantation 
studies with brain tissue from Prnp+/+ infected donor animals to Prnp-/- recipient 
mice identified pathologic changes only in transplanted cells expressing PrPC 
(Blattler et al., 1997). Furthermore, transgenic mice expressing a soluble form of 
PrPC lacking the glycosylphosphatidylinositol (GPI) anchor sequence on a Prnp-/- 
background inoculated with prions revealed that conversion and accumulation of 
PrPSc in the CNS was not greatly altered, however the onset of symptoms and 
pathogenesis were vastly delayed (Chesebro et al., 2005). Finally, spatial and 
temporal correlations between PrPSc accumulation and neuropathological 
changes are weak or lacking (Tremblay et al., 1998; Chiesa et al., 2000; Mallucci 
et al., 2003). All these data indicate that PrPSc is central to the propagation of 
infectivity but it is only indirectly involved in disease pathogenesis. 
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2.2 PrPC plays a central role in  prion disease pathogenesis 
Several models have been proposed by which PrP C can cause 
neurodegeneration (Wong et al., 2000; Chiesa & Harris, 2001; LeBlanc & 
Roucou, 2003; Harris & True, 2006). A group of studies suggests that PrPC 
normally exerts a neuroprotective function by protecting cells from oxidative 
stress. Upon infection this function is lost causing increased oxidative stress 
mediated damage (Milhavet et al., 2000; Wong  et al., 2001; Brown, 2005). 
Consistent with this loss of function hypothesis it has been shown that mice and 
humans infected with prions reveal increased oxidative stress in brain regions 
with PrPSc deposits (Guentchev et al., 2000; Guentchev et al., 2002). It remains 
however unresolved why Prnp-/- mice show no phenotype (Bueler et al., 1992; 
Manson et al., 1994) if a loss of PrPC function is the cause of disease.  
Also a model by which PrPC leads to toxicity mediated by a gain of function has 
been proposed (Chiesa & Harris, 2001; Harris & True, 2006). The induction of a 
transmembrane form of PrP, termed CtmPrP, during prion disease has been 
implicated in PrPC-mediated neurotoxicity (Hegde et al., 1998a; Hegde et al., 
1999; Stewart et al., 2005). Two lines of evidence suggest CtmPrP expression is a 
determinant of pathogenesis in infectious prion disease. First, the time point of 
disease onset upon inoculation with prions inversely correlates with the absolute 
amount of CtmPrP expressed in the murine brain. Higher levels of constitutive 
CtmPrP expression at the time point of infection relate to shorter incubation 
periods (Hegde et al., 1999). Second, upon infection with PrPSc, an increase in 
CtmPrP expression was detected which closely followed the time course of 
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pathogenesis (Hegde et al., 1999). Increased expression of CtmPrP has been also 
associated with Gerstemann-Straussler-Scheinker syndrom (GSS) - a human 
genetic prion disease - where an alanine to valine substitution at amino acid 
residue 117 (A117V) of PrP renders the potential transmembrane domain of PrP 
more hydrophobic increasing the propensity of nascent PrP chains to be 
synthesized during cotranslational translocation in the CtmPrP isoform (Hegde et 
al., 1998a). In conclusion, there is evidence that PrPC plays a role in the 
pathogenesis of prion diseases however it remains unclear whether this is due to 
a loss of protective PrPC function or a gain of a PrPC mediated toxic function. 
 
2.3 Physiological functions of PrPC 
While the establishment of Prnp-/- mice has been very valuable for understanding 
the role of PrPC in the transmission of prion disease, these mice have been 
somewhat disappointing in regard to understanding the normal cellular function 
of PrPC. Prnp-/- mice seem to develop normally (Bueler et al., 1992; Manson et 
al., 1994) and show only limited phenotypes such as mild alterations in sleep 
pattern (Tobler et al., 1997) or synaptic transmission (Collinge et al., 1994; Curtis 
et al., 2003; Maglio et al., 2004) although this last function has not been 
observed by all (Lledo et al., 1996). The lack of an obvious phenotype in Prnp-/- 
mice is puzzling in light of the strong conservation of PrP across mammalian 
species (van Rheede et al., 2003). Perhaps the normal function of PrPC is so 
important that it has a redundant backup mechanism which takes over in Prnp-/- 
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mice. Alternatively, the normal functions of PrPC may only be revealed under 
certain conditions.  
A growing body of evidence indicates that PrPC is implicated in cellular survival 
and neuroprotection. The neuroprotective role of PrPC as an anti-oxidant protein 
has been well demonstrated. PrPC has been shown to have superoxide 
dismutase activity (Brown et al., 1997; Brown et al., 1999). Cerebellar neurons 
derived from the Prnp-/- mice are more susceptible to oxidative stress than their 
wild-type (wt) PrP expressing counterparts and the mice themselves show 
evidence of increased oxidation of proteins and lipid peroxidation (Wong et al., 
2001; Brown et al., 2002; McLennan et al., 2004). A neuroprotective function of 
PrPC has also been demonstrated for Bcl-2-associated protein X (Bax)-induced 
apoptosis (Bounhar et al., 2001). Bax is a major neuronal pro-apoptotic member 
of the Bcl-2 family (Yin et al., 1994). Microinjection of human primary neurons in 
culture with a cDNA expressing high levels of Bax is sufficient to induce Bax-
specific apoptosis (Bounhar et al., 2001), while co-injection with wild type PrP 
completely protected neurons against Bax-mediated cell death as is observed 
with the anti-apoptotic protein, Bcl-2. The neuroprotective function of PrPC is 
supported by in vivo experimental evidence. A single copy of the Prnp gene can 
rescue the ataxic transgenic PrPD32-121 or PrPD32-134 mice from neuronal cell 
death of the cerebellar granular layer (Shmerling et al., 1998). PrPC also rescues 
mice from the prion-like Doppel induced neuronal cell death and 
neurodegeneration (Moore et al., 1999) which has recently been shown to be 
Bax-mediated (Heitz et al., 2007). Furthermore, PrPC protects mice against 
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seizures and epilepsy-inducing drugs (Walz et al., 1999). Whether these 
neuroprotective pathways exhibited by PrPC are all dependent on Bax or share 
another common pathway remains unresolved. 
In contrast, a body of evidence suggests PrPC exerts a neurotoxic role triggering 
apoptosis. Cell lines and primary neurons expressing wt PrPC are susceptible to 
apoptosis with a low dose of staurosporine which causes caspase-3 activation 
(Paitel et al., 2004) a key executioner molecule of the apoptotic cascade (Porter 
&  Janicke, 1999), whereas cells derived from Prnp-/- mice are less vulnerable to 
this same treatment. Additiona lly, overexpression of wt PrPC has also been 
shown to trigger caspase-3 activation and apoptosis (Paitel et al., 2002). Another 
study has shown that PrPC can trigger cell cycle arrest when overexpressed in 
cultured cells (Gu et al., 2006). The neurotoxic property of PrPC has also been 
demonstrated in vivo. Overexpression of PrPC in transgenic mice can result in 
ataxia and lead to neurodegeneration (Westaway et al., 1994). Taken together it 
remains unclear why in some studies PrPC reveals neuroprotective and in other 
instances neurotoxic properties.  
 
2.4 Secretory protein biogenesis 
Secretory and membrane proteins traverse the secretory pathway which consists 
of the endoplasmic reticulum (ER), Golgi network and endosomal vesicles. They 
are initially synthesized in the cytoplasm and rapidly targeted to the ER 
membrane where the nascent protein while continuing to be synthesized is 
translocated into the ER lumen (Palade, 1975). Targeting to, and translocation 
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across, the ER membrane is driven by interaction of the signal sequence of the 
nascent chain with a series of receptor proteins, first in the cytoplasm (Signal 
Recognition Particle, SRP) and then at the outer ER membrane with the SRP 
receptor and the Sec61 complex (Walter &  Johnson, 1994). As a result of these 
interactions a complex protein-conducting channel is opened termed the 
translocon which consists of the hetero-trimeric Sec61 complex, allowing the 
nascent chain to cross the ER membrane and enter the ER lumen where it is 
initially encountered by luminal chaperones like binding protein (BIP) which 
prevent unintended interactions and shields nascent proteins to facilitate correct 
folding (Johnson &  van Waes, 1999). Transmembrane (TM) and multispanning 
membrane proteins are synthesized by the partitioning of the translocon and 
integration of the TM domain within the lipid bilayer by a yet undefined 
mechanism (Pitonzo &  Skach, 2006). In addition to the Sec61 complex the 
translocation of many substrates requires additional factors such as the 
translocating-chain associated membrane protein (TRAM; Hegde et al., 1998c), 
or translocation-associated protein (TRAP; Hegde et al., 1998b, Fons et al., 
2003). Contemporaneous with the emergence of the nascent chain to the ER 
lumen several further covalent modifications such as N-linked glycosylation 
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2.5 Quality control mechanisms of protein folding in the secretory pathway  
The cell has developed a stringent quality control mechanism to ensure only 
bona fide folded secretory and membrane proteins leave the ER and that 
proteins that fail to pass the quality control are rapidly disposed of to maintain the 
secretory capacity (Molinari &  Sitia, 2005). In most cases it seems that control 
over N-glycan maturation is utilized as a mechanism to sort correctly folded 
proteins from those that fail to establish a native conformation.  
While the nascent chains exits the translocon and enters the ER lumen it is 
scanned for an asparagine-x-serine/threonine consensus motif by the 
oligosaccharide transferase complex at which once encountered a pre-
assembled, tri-antennary glycan composed of two N-acetylglucosamine, nine 
mannose and three glucose residues are covalently attached to the asparagine 
residue (Helenius &  Aebi, 2004). Subsequently, the two outermost glucose 
residues are removed by glycosidases I and II (Hebert et al., 2005). The nascent 
or newly synthesized protein then binds to calreticulin and /or calnexin which 
together with the oxidioreductase ERp57 shield the nascent protein and assist 
correct disulfide bond formation (Ellgaard et al., 1999). To release the bound 
chains from calnexin and calreticulin, glucosidase II removes the remaining 
glucose residue and the protein can now be shuttled to the Golgi unless 
recognized by a UDP-glucose glucosyltransferase, which reglucosylates 
incorrectly folded glycoproteins (Hebert et al., 2005). If reglucosylated the 
glycoprotein is bound again by calnexin and calreticulin and stays in the cycle 
until correctly folded or targeted for ER associated degradation (ERAD) by 
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retrotranslocation to the cytoplasm where degradation by the ubiquitin-
proteasome system occurs (Ellgaard &  Helenius, 2003). 
Upon shuttling of correctly folded glycoproteins to the Golgi further processing  
occurs with the removal of core mannose residues and further protein specific 
glycan modifications (Herscovics, 1999). Biochemical analysis with 
Endoglycosidase H (Endo H) is used to detect proteins that have passed quality 
control and have exited to a post-ER compartment hence enabling detection of 
bona fide folded proteins  (Hegde et al., 1998a). 
Some proteins appear to have an intrinsic propensity for misfolding leading to a 
high fraction being degraded, as commonly observed for polytopic membrane 
proteins like cystic fibrosis transmembrane conductance regulator (Sadlish &  
Skach, 2004). In the case of PrP, in some instances little misfolding is seen for wt 
PrP however several mutants including one favoring CtmPrP remain Endo H 
sensitive (Stewart et al., 2001). Yet this observation has at least in part been 
contested by observations in transgenic (Tg) mice where CtmPrP favoring mutants 
including the same mutant that showed ER-retention reveal resistance to Endo H 
treatment (Hegde et al., 1998a; Stewart & Harris, 2005). The question why the 
quality control machinery permits CtmPrP to exit the ER in vivo despite leading to 
neurodegeneration remains unresolved. 
 
2.6 PrP biogenesis and topological heterogeneity 
PrP is a 27 - 33 kD sialated glycoprotein with two N-linked glycosylation sites, a 
disulfide bond, an N-terminal cleaved signal sequence (SS), a C-terminal GPI 
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anchor sequence, an octapeptide motif rich in histidines consisting of 4-5 repeats 
termed the octarepeat (OR) domain (Figure 2; Prusiner et al., 1998) and a 
hydrophobic domain of approximately 24 hydrophobic or uncharged residues that 
could serve to span the lipid bi-layer. It is notable that it is enriched in glycine (7 
residues) and alanine (6 residues), resulting in a somewhat diminished 
hydrophobicity, compatible with transmembrane (TM) domain integration, but 
significantly lower than is typical for membrane-spanning regions of many other 
integral membrane proteins which are rich in leucine, isoleucine, and valine (Ott 
& Lingappa, 2002). Additionally, PrP contains a sequence termed the stop 
transfer effector (STE) sequence, identified as a charged domain just N-terminal 
to the hydrophobic domain, which was shown to govern membrane integration of 
the TM domain (Yost et al., 1990). Other work suggests that the STE concept 
may apply more generally to conventional integral membrane proteins, as an 
STE has been defined for transmembrane the immunoglobulin M heavy chain 
(Falcone  et al., 1999). 
 
 
Legend Figure 2. Domain structure of PrP. Schematic diagram of domains of the PrP 
coding region. The N-terminal signal sequence (SS), the octarepeat domain (OR), the stop 
transfer effector sequence (STE), the potential membrane spanning domain (TM), potential N-
linked glycosylation sites (CHO), disulfide bond (S-S) and the C-terminal glycosylphophatidyl-
inositol anchor sequence (GPI), are displayed. Numbering refers to the Syrian hamster PrP 
amino acid sequence. 
Figure 2 
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Cell-free translation systems have been shown to faithfully reproduce the 
lumenal localization of classical secretory proteins (Lingappa et al., 1978) and 
the transmembrane topology of integral membrane proteins (Katz et al., 1977).  
When studied in these systems however, nascent PrP was unusual in that it gave 
rise to both transmembrane and secretory forms of the full length protein (Hay et 
al., 1987a; Hay et al., 1987b). Since both N- and C-terminal domains of the 
transmembrane form were found at the luminal surface, the initial assumption 
was that the protein spanned the membrane twice. Later, with the development 
of the monoclonal antibody specific for the STE domain of PrP, it was observed 
that both N- and C-terminal immunoreactive fragments after proteolysis 
contained this epitope. Hence it was recognized that these domains were derived 
from separate populations of chains, each spanning the membrane once in one 
direction or the other (Hegde et al., 1998a; Hegde et al., 1998b; Hegde et al., 
1999; Stewart & Harris, 2001). The form that spans the membrane with its C-
terminus in the ER lumen was termed CtmPrP. The fully translocated form 
attached to the membrane only by a C-terminal GPI-anchor was termed SecPrP. A 
third form, spanning the membrane with N-terminal domain oriented in the ER 
lumen, was termed NtmPrP. 
In vivo the expression of CtmPrP has previously been found solely in the context 
of disease model systems (Hegde et al., 1998a; Hegde et al., 1999; Stewart et 
al., 2005) whereas the detection of NtmPrP has been limited to hematopoietic cells 
from patients with a genetic GPI-anchoring deficiency (Risitano et al., 2003). 
SecPrP and its N-terminally truncated form, termed C1 (Vincent et al., 2001), are 
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the only prominently detected forms found under normal physiologic conditions 
(Hegde et al., 1998a; Stewart et al., 2005). 
 
2.7 Detecting topological isoforms of PrP 
The detection of the three topological isoforms of PrP is based on accessibility of 
exposed residues to proteolysis with Proteinase K (PK, Figure 3A and C; Hegde 
et al., 1998a), which is henceforth referred to as the topological assay.  Fully 
translocated SecPrP remains shielded from proteolysis whereas CtmPrP and NtmPrP 
are partially cleaved revealing a band shift on autoradiographs (Figure 3C; 
Hegde et al., 1998a) corresponding to the cleavage of exposed residues to the 
cytoplasm. Addition of non-denaturing detergents under these conditions 
completely degrades all topological PrP forms. In addition to the topological 
assay based on orientation across the membrane, it was found that CtmPrP could 
be scored by a conformational assay involving relatively mild PK resistance in 
non-denaturing detergent solution, i.e. under conditions where all topological 
differences had been abolished (Figure 3B and C; Hegde et al., 1998a). Thus, 
the three newly synthesized forms of PrP differ both in topology and intrinsic 
conformation. 
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Legend Figure 3. Detection of topological isoforms of PrP. (A) Schematic of the 
topological assay. As shown, vesicles shield proteins from proteolysis, therefore protecting 
SecPrP from proteolysis, whereas the exposed residues of CtmPrP and NtmPrP are accessible to 
proteolysis. (B) Schematic of the conformational assay. Addition of non-denaturing detergent 
abolishes all topological differences, so that mild proteolysis in this scenario is directed 
towards conformational differences (Hegde et al., 1998a). Treatment with mild protease under 
these conditions demonstrates intrinsic differences in folded state by protection of a signature 
fragment of CtmPrP. (C) Topological and conformational analysis of PrP in cell-free translation 
coupled translocation by mild proteolysis with proteinase K (PK). PrP was translated in the 
absence (lane 1) or presence of rough microsomes (Mb, lanes 2-4). Mb were either left 
untreated (lane 2) or treated with PK under mild conditions (0.25 mg/ml) in the absence (lane 
3) or presence (lane 4) of non-denaturing detergent and resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) and autoradiography (AR, Hegde  et al., 
1998a). Lanes 1-3 demonstrate the topological assay, Lane 4, the conformational assay. Not 
shown under harsher PK conditions (>0.5mg/ml) the topological assay remains unaffected 
whereas the conformational assay reveals a loss of signal (Hegde et al., 1998a).  
Figure 3 
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2.8 A hypothesis driven study 
While many studies implicate PrPC in cellular survival with anti-oxidant (Wong et 
al., 2001; Brown et al., 2002), neuroprotective (Chiarini et al., 2002; Roucou et 
al., 2004) and anti-apoptotic (Bounhar et al., 2001) features, other evidence 
suggests that PrPC mediates cell death and disease (Westaway et al., 1994; 
Shmerling et al., 1998; Paitel et al., 2003). Studies on the biogenesis of PrP 
provide a potential explanation for these dichotomous observations on PrPC 
function. It has been shown that PrP can be made in three topologically distinct 
isoforms: SecPrP; CtmPrP and NtmPrP (Hegde et al., 1998a).  
Based on the aforementioned observations the hypothesis was proposed that 
PrPC may have both toxic and protective functions depending on changes in 
relative or absolute  expression levels  of different topological isoforms of PrPC. 
The aim of this thesis was to test the hypothesis if PrPC may consist of multiple 
topological isoforms with potentially distinct roles in physiological or pathological 
contexts. To dissect the functional roles of CtmPrP and SecPrP, advantage of 
mutants was taken which were known to extensively alter the ratio of each 
topological isoform. A comparative functional analysis of wt PrP expression in 
relationship to mutants favoring CtmPrP or SecPrP expression enabled me to 
determine if both forms are active within PrPC and to determine what their roles 
may be. 
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3. Material and Methods 
 
3.1 Reagents 
If not stated otherwise salts, acids, buffers and detergents were purchased from 
SIGMA (St. Louis, Mo. USA); all inhibitors were purchased from Calbiochem 
(San Diego, CA, USA). Unless stated otherwise ultrapure water was prepared 
using reverse osmosis, ultra filtration and UV treatment apparatus Milli-Q 
(Millipore, Billerica, MA, USA).  
Antibodies directed to PrP; mouse monoclonal antibody (mAb) 13A5 (Lowenstein 
et al., 1990), Hamanized Fab ‘2 D18 (Leclerc et al., 2003), and rabbit polyclonal 
RO73 (Serban et al., 1990) were kind gifts from Dr. Stanley Prusiner’s laboratory 
(UCSF, San Francisco, CA, USA). TRAPa rabbit anti-sera was kindly provided 
by Dr. Manu Hegde (NIH, Bethestha, DM, USA). All other antibodies were 
obtained from commercial sources as stated. 
 
3.2 General procedures 
Unless stated otherwise all methods including deoxyribonucleic acid (DNA) 
cloning and purification, polymerase chain reaction (PCR), sodium dodecyl 
sulfate (SDS) polyacrylamide gel electrophoresis (PAGE), immunoprecipitation 
(IP), Western-blotting, immunocytochemistry (ICC) and immunohistochemistry 
(IHC) were performed according to standard procedures (Celis, 1998; Sambrook 
& Russell, 2001; Hayat, 2004). 
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3.3 DNA constructs 
DNA constructs for cell culture experiments were engineered by subcloning the 
open reading frame of SHaPrP (SWISS-PROT: P04273; Basler et al., 1986) and 
its mutants which have been previously characterized (Hegde et al., 1998a) from 
pSP64 (Promega, Madison, WI, USA) into pcDNA3.1 Zeo+ (Invitrogen, Calsbad, 
CA USA) by utilizing Bam HI and Eco RI sites. Three mutants were mainly used 
throughout this study, two favoring the expression of CtmPrP by substitutions  
K110I, H111I, termed KH®II and A117V albeit the A117V favors CtmPrP 
expression to a much lesser extent than the KH®II mutant. Another mutant with 
a deletion of the STE domain, D103-114, termed DSTE diminishes the  capacity of 
PrP to be expressed as CtmPrP, however greatly favors the expression of SecPrP 
(Hegde et al., 1998a). 
Human Bcl-2 and human Bcl-XL were kind gifts from Dr. Andrea LeBlanc (McGill 
University, Montreal, Canada) and were engineered into pcDNA 3.1 zeo + using 
Kpn I/ Xho I and Eco RI/ Bam HI sites respectively. All DNA sequences were 
verified by DNA-sequencing.   
 
3.4 Transgenic mice 
Transgenic mice used in this study—Tg(SHaPrP,KH®II)F1198; Tg(SHaPrP, 
DSTE)F1788; Tg(SHaPrP)A3922—have been previously described (Hegde et al., 
1998a) and were constructed on a Prnp-/- background (Bueler et al., 1992).  
Double Tg(tTA:mPrP) and Tg(mPrP), 4053 mice on a Prnp-/- background have 
also previously been described (Tremblay et al., 1998) and were made by 
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crossing parental lines Tg(Prnp-tTA)F595 with Tg(tetO-PrP)E6740 to make 
bigenic Tg(Prnp-tTA:tetO-PrP)E6740/F959, which were then bred to 
homozygosity and termed Tg(tTA:mPrP). Temporal regulation of PrP expression 
in these mice was achieved by facilitating a reverse tetracycline-controlled 
transactivator (tTA) driven by the PrP gene control elements to ensure tissue-
specific expression of PrP on a Prnp-/- background as has been previously 
described (for details, see legend to Figure 4; Tremblay et al., 1998). Systemic 
administration of doxycycline (dox), an analogue of tetracycline, in the drinking 
water of Tg(tTA:mPrP) mice results in suppression of PrP expression, whereas 
its withdrawal enables PrP expression. Dox was provided at 0.02 mg/ml in 
drinking water supplemented with 5% sucrose in light-protected bottles. 
All mice were maintained on an inbred FVB background, were provided food and 
water ad libitum and were cared for according to the guidelines provided by the 
University of California. Euthanasia was performed by placing mice in a gas 
chamber saturated with CO2 for a few minutes until mice were no longer 
responsive. After cervical dislocation mice were decapitated, brains carefully 
dissected and further processed according to experimental demands described 
in the appropriate sections. 
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3.5 Inoculation of mice with Sc237 prions 
Tg mice were inoculated with hamster Sc237 prions as previously described 
(Hegde et al., 1999). Briefly, intracerebral inoculation was performed with 30 µl of 
1% (w/v)  hamster brain homogenate  prepared in PBS that had been derived from 
terminally sick hamsters inoculated with hamster prions Sc237. Mice were 
 Legend Figure 4. Transgenic mice.  Tetracycline-dependent, tissue-specific expression of 
PrPC in transgenic (Tg) mice, termed Tg(tTA:mPrP), have been previously described 
(Tremblay et al., 1998) and were engineered on a Prnp-/- background. (A) In the absence of 
doxycycline (dox), a tetracycline analogue, the transactivator (tTA) is expressed from the 
Syrian hamster (SHa) PrP  gene control elements (PPrP) binds to the tet response element 
(TRE), which facilitates transcription of the mouse PrP gene (Prnp) from a minimal 
Cytomegalovirus promoter (PCMV). (B) Administration of dox (black rectangle) leads to the 
silencing of PrPC expression, by binding to the tTA and inducing a conformational change, 
reducing affinity for TRE and thus silencing Prnp transcription. (C) All other Tg mice used in 
this study were made by placing the Prnp gene (including mutants) under direct control of 
PPrP. 
Figure 4 
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maintained under normal conditions and provided food and water ad libitum. 
When clinical symptoms typical of neurodegeneration were first observed data 
was recorded and mice were killed. Brains were carefully extracted and half 
brains placed in 10% buffered formalin for IHC while the other half was 
homogenized, frozen in liquid nitrogen and stored at -80 °C until needed for the 
detection of PK resistant PrPSc. 
 
3.6 Biochemical analysis of PrPC topology in mouse brains 
Ten-percent (w/v) whole brain homogenates were prepared from fresh tissue in 
ice-cold homogenization buffer composed of 0.25 M sucrose (Fisher Scientific, 
Pittsburg, PA, USA), 100 mM KCl, 5 mM MgAc2 and 50 mM HEPES (pH 7.5) by 
10 strokes with a teflon pestle homogenizer (Wheaton, Millville, NJ, USA), rapidly 
frozen in liquid nitrogen and stored at -80°C until further use. Topological and 
conformational assays were performed in principle as previously described 
(Hegde et al., 1998a). Brain homogenates were rapidly thawed, placed on ice 
and diluted in cold homogenization buffer to a final concentration of 2% (w/v). 
Each sample was aliquoted into three tubes on ice: the first remained untreated, 
the second was treated with 0.25-1 mg/ml PK (Merck) for topological analysis 
and the third tube was treated with 0.5% (v/v) TritonX-100 and 0.25 mg/ml PK for 
the conformational analysis. Samples were incubated for 1 hour (h) on ice at 4°C 
upon which the PK reaction was terminated with 1 mM phenylmethanesulfanyl 
fluoride (PMSF, Sigma, St. Lous, MO, USA), was further incubated for 5 min on 
ice and transferred to 4 volumes of denaturation buffer consisting of 1% SDS, 50 
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mM Tris-Ac pH 8.0 which had been heated in a boiling water bath and incubated 
for 5 min. After cooling down to room temperature (RT) samples were diluted 
with 1 volume 2% 2-mercaptoethanol (BME, Sigma), 50 mM Tris-Ac pH 8.0, 
incubated for 15 min at 37°C and then 2 min at 99°C, cooled to RT and TritonX-
100 added to a final concentration of 0.5% (v/v). After thorough mixing 
deglycosylation was performed with 200 Units PNGase F (New England Biolabs, 
Ipswitch, MA, USA) overnight at 37°C. The following day samples were placed 
on ice and precipitated with a final concentration of 10% (w/v) tri-chlor-acetate 
(TCA), sedimented for 5 min at 10,000 g. The supernatant was aspirated and 
washed with 1 volume ice-cold ethanol and ether (1:1), pellets were left to air dry 
for ~10 min and resuspended in 1x SDS samples buffer 1% (w/v) SDS, 25mM 
Tris pH6.8, 0.01% (w/v) bromphenolblue (Sigma), 25% (v/v), glycerol, 100 mM 
dithiothreitol (DTT) in a three fold greater volume than the initial 10% 
homogenate. Typically 20 µl of 10% homogenate was used per tube treated with 
PK and one-fourth there of was resolved by 0.75 mm thick 12.5% Tris-Tricine 
SDS-PAGE. Gels were transferred to nitrocellulose in 1.3 l transfer buffer 
containing 156 mM Glycine, 80 mM Tris, 20% (v/v) Methanol (VWR, West 
Chester, PA, USA) for 90 min at 50 volts with a Criterion tank transfer apparatus 
containing plate electrodes (Biorad). Quality of transfer was assessed by staining 
nitrocellulose membrane with 0.01% (w/v) Imidio black for 10 min. Only 
membranes with ensured even transfer lacking any obvious artifacts were further 
processed. Membranes were blocked for 30 min in 5% (w/v) fat-free dry milk 
(Carnation, Nestle, Vervey, Switzerland) in phosphate buffered saline (PBS) with 
3. Material and Methods   31 
0.025% (v/v) Tween 20 (PBST) at RT on a rocking platform. The membrane was 
cut at the 50 kD marker (Precision, Biorad). The top section was probed against 
GRP94 (Stressgen, Ann Arbor, MI, USA) at 1:10,000 to control for loading and 
ER integrity. The bottom part of the membrane was probed against PrP with mAb 
13A5 or humanized Fab’2 D18 at 1:1,000 overnight at 4°C on a rocking platform. 
Subsequentially, blots were washed 4 times at 5 min each with 1% fat-free dry 
milk with PBST and then incubated 1-4 h at RT with the corresponding anti-
rabbit, mouse or human Fab’2 secondary antibody conjugated to horseradish 
peroxidase (HRP) (all Pierce, Rockford, IL, USA) at 1 µg/ml. Membranes were 
then washed 6 times with PBS and developed with chemiluminescent Super 
Signal Substrate West Pico or Femto (Pierce) according to the manufactures 
guide lines and exposed to Biomax XR film (Kodak, Rochester, NY, USA). 
 
3.7 Enhanced detection of CtmPrP in brain homogenates  
The enhanced detection of CtmPrP in non-Tg FVB mice was in principle 
performed as described above (3.6) for the topological assay however PrP was 
further enriched prior to SDS-PAGE by IP. After denaturation samples were 
diluted to a final concentration of 0.2% SDS, 0.75% Triton X100, 0.375% 
deoxycholate, 37.5 mM KCl, 50mM Tris-Ac pH 8.0 supplemented with EDTA-free 
Protease Inhibitor Cocktail Tablets (Roche, Palo Alto, CA, USA) according to the 
manufacturer’s instructions. Samples were then thoroughly mixed, 200 U 
PNGase F was added and incubated overnight at 37 °C. The following day after 
deactivation of enzymes by heating samples 10 min at 90 °C, samples were left 
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to cool for ~10 min at RT then were placed on ice and 30 µl (50%) Protein A 
(Biorad) that had been preequilibrated with IP buffer was added and tubes placed 
for 1-6 h on a top–to bottom rotation wheel at 4°C after which samples were 
sedimented for 10 min at 16,000 g. 90% of the supernatant typically 1.8 ml was 
transferred to a new tube and IP performed with 10 µl anti-PrP polyclonal RO73 
and 60 µl (50%) Protein A overnight with top to bottom rotation at 4°C. Samples 
were washed 3 times in 1 volume IP buffer and once in 50 mM Tris-Ac pH 8.0. 
After drying beads for 15 min at 99°C they were resuspended in 60 µl sample 
buffer; 30 µl was resolved by 12.5% Tris-Tricine SDS-PAGE, then transferred to 
nitrocellulose and probed overnight at 4°C. Below the ~50 kD marker 
membranes were probed with D18 directly conjugated to HRP (kindly provided 
by Hana Serban, Prusiner laboratory) at 0.2 µg/ml and above ~50 kD with anti-
Rabbit-HRP (Pierce) at 1:10,000. Membranes were washed and developed as 
described above (3.6). The use of directly conjugated HRP to anti-PrP D18 was 
proved an imperative step to obtain a sufficient signal to noise ratio to detect 
CtmPrP in wild-type non-transgenic FVB mice. It should be noted that despite 
extensive optimization attempts with secondary antibodies that supposedly only 
detect non-reduced forms of IgG (Trueblot, eBioscience, San Diego, CA, USA) 
the background 25 kD IgG light chain cross reactivity could not be eliminated 
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3.8 Glycan maturation analysis of CtmPrP and SecPrP 
Brain homogenates that had been processed by the topological assay (See 3.6) 
and denatured in denaturation buffer were reduced with 1 volume 2% BME 
(BME, Sigma), 100 mM Tris-Ac pH 8.0 incubated for 15 min at 37°C and 2 min at 
99°C. After cooling to RT, TritonX-100 was added to a final concentration of 0.5% 
(v/v) and sodium citrate pH 5.5 was added to a final concentration of 100 mM. 
After thorough mixing the sample was divided into three tubes. One was left 
untreated, the second was treated with 200 Units PNGase F and the third was 
treated with 300 U Endoglycosidase H (Endo H, NEB). Samples were incubated 
overnight at 37°C, precipitated with TCA and Western-blotted as describe above. 
In addition to PrP and GRP94, blots were also probed with anti-TRAPa at 
1:5,000 which being an ER-resident glycoprotein served as a positive control for 
Endo H treatment. 
 
3.9 Biochemical detection of PrPSc 
PrPSc was detected by proteolysis with PK as previously described (Hegde et al., 
1999). Briefly, 2% (w/v) brain homogenates were treated with 0.5 mg/ml PK for 
1 h at 37 °C in buffer containing a final concentration of 10 mM Tris-Ac (pH 8.0), 
150 mM NaCl, 0.5% TritonX-100 and 0.5% deoxycholic acid. The reaction was 
terminated with 4 volumes ice cold methanol precipitation, sedimented for 5 min 
at 10,000 g and air dried pellets resuspended in SDS sample buffer, resolved by 
15% Tris-Glycince SDS-PAGE, transferred to nitrocellulose and probed with anti-
PrP 13A5 as described above (3.6). 
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3.10 Measurement of lipid peroxidation in brain homogenates 
Lipid peroxidation was measured using a BIOXYTECH MDA-586 assay kit (Oxis 
International) by assessing the level of malondialdehyde (MDA) following the 
manufacturer’s protocol with minor modifications. Dissected hippocampi were 
homogenized in 0.1 M phosphate buffer (pH 7.4) and centrifuged at 20,000 g at 
4 °C for 30 min. Protein concentrations of the supernatants were determined with 
the BCA kit (Pierce) and 75 µg of protein (50 µl) was incubated with 2.5 µl 
probucol, 160 µl diluted R1 reagent and 37.5 µl of R2 at 45 °C for 60 min. The 
reaction mixture was then centrifuged at 10,000 g for 10 min and optical density 
of the supernatant was determined at 586 nm using a Beckman 
Spectrophotometer. MDA concentration was calculated based on TMOP 
standard curve. 
 
3.11 Analysis of PrP topology in transfected CHO-KI cells 
CHO-KI cells (ATCC: CCL-61) were maintained in Ham’s F12 (UCSF, cell culture 
facility, CCF), 10% Fetal bovine serum (FBS, Hyclone, Logan, UT, USA) 
supplemented with penicillin and streptomycin (CCF) in a humidified incubator 
with 5% CO2 at 37°C.  24 h prior to transfection 4x105cells were plated in 35-mm 
wells (6-well plate) and transfection was performed with Lipofectamine Plus 
(Invitrogen) according to the manufacturer’s guidelines with 3 µg DNA, 5 µl 
Lipofectamine and 7.5 µl Plus reagent per well and cells harvested 24 h 
thereafter. 4.5 h prior to harvesting the media was changed to cystein and 
methionine free Hams’ F12 (CCF) with dialyzed FBS (Hyclone). ~0.25 mCi S35 
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labeled cystein and methionine (Easy Tag, Perkin Elmer, Costa Mesa, CA, USA) 
was added and cells were incubated for 4 h prior to harvest. Cell culture plates 
were placed for 10 min on ice and then mechanically detached by scraping cells 
in media, washed 2 times with ice cold PBS by sedimentation at 1,000 g and 
resuspended in 600 µl hypotonic lysis buffer consisting of 10 mM HEPES pH 7.4 
and incubated 20 min on ice prior to lysis by 10 passages through a 30 gauge 
syringe (BD Biosciences, San Jose, CA, USA). Samples were adjusted to a final 
concentration of 50 mM KCl, 5 mM MgAc2, 50 mM HEPES (pH 7.4). Proteolysis 
of samples with PK was performed as described above (see 3.6). After 
PNGase F treatment and heat deactivation samples were pre-cleared and 
immunoprecipitated with 2 µl mAb13A5 and 30 µl (50%) Protein G (ImmunoPure, 
Pierce). Samples were then washed and resuspended in 60 µl sample buffer; 
15 µl was resolved by SDS-PAGE on 12.5% Tris-Tricine gels and visualized by 
AR by exposing to Biomax XR film. 
 
3.12 TUNEL and caspase-3 analysis of transfected CHO-KI cells 
CHO-KI cells were maintained and transfected as described above (3.11) 
however transfection was performed with 0.6 µg DNA, 1 µl Lipofectamine and 
1.5 µl Plus reagent per well. Cells were plated in 15-mm wells with glass 
coverslips (Fisher Scientific) at 5x104 cells per well. After 48 h, cells were fixed on 
ice for 15 min with 4% paraformaldehyde in PBS. The cells were then washed 
twice and blocked for 30 min with 5% (w/v) BSA , 0.5% (w/v) saponin in PBS and 
washed 3 times with PBS then stained for TUNEL by the In Situ Death Detection 
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kit (Roche, Palo Alto, CA, USA) according to the manufacturer’s instructions  
using 17 µl of a 20 fold diluted enzyme solution and incubated 1 h at 37 °C in a 
humidified chamber. Alternatively, fixed cells were stained for activated 
caspase-3 by probing with rabbit polyclonal specific for the activated form (Cell 
Signaling, Billerica, MA, USA) according to the manufacturer’s guideline by 
probing at 1:20 diluted in 1% BSA in PBS overnight at 4 °C. After washing four 
times with PBS, subsequently all cells were stained for PrP by probing with mAb 
13A5 at 1:100 for 1 h at RT, washed 4 times with PBS, followed by incubation for 
30 min at RT in the dark with secondary goat anti-mouse antibody conjugated to 
Alexa 594 and/or anti-rabbit conjugated to Alexa 488 (Molecular Probes) diluted 
at 1:500 in PBS with 1% BSA. Coverslips were then washed four times in PBS 
counterstained with DAPI (Molecular Probes, Eugene, OR, USA) and coverslips 
mounted on slides with aqueous mounting medium (Pro Long, Molecular 
Probes). 
 
3.13 TUNEL analysis of transfected CHO-KI cells treated with caspase-3 
and Bax inhibitors 
Caspase-3 and Bax are two pro-apoptotic molecules know to participate in the 
execution of apoptosis that leads to the fragmentation of DNA (Korsmeyer, 1995; 
Porter & Janicke, 1999). Hence by blocking their activation with pharmacological 
inhibitors permits the study of their participation in PrP mediated apoptosis. 
Experiments were conducted exactly as stated above under 3.12 however with 
the exception that cells were treated 30 min prior to transfection with either 
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10 µM Z-DEVD-FMK (caspase-3 inhibitor), 100 µM V5 (Bax inhibitor) or an equal 
volume of the solvent dimethylsolfoxide (DMSO) alone. 
 
3.14 TUNEL analysis of transfected CHO-KI cells overexpressing Bcl-2 or 
Bcl-XL 
Bcl-2 and Bcl-XL belong to the Bcl-2 homology (BH) family of proteins just like 
Bax however with anti-apoptotic properties which have also been shown to offset 
the pro-apoptotic effect of Bax (Korsmeyer, 1995). The protective effect of Bcl-2 
and Bcl-XL against CtmPrP mediated apoptosis was tested by preparing CHO-KI 
clonal cell lines that were expressing either Bcl-2 or Bcl-XL or an empty pcDNA 
3.1 Zeo+ plasmid (Mock) which had been selected and maintained with 
0.25 mg/ml Zeocin (Invitrogen) in complete media.  Screening of Bcl-2 and 
Bcl-XL cell lines was performed by Western-blot. Clones with the highest 
expression level were used for experiments with two independent clones tested 
for each candidate. Experiments were then performed as described above (3.12) 
by transfection with KH®II and then probing for apoptosis by TUNEL. 
 
3.15 Viability analysis of SecPrP mediated protection to oxidative stress in 
cultured cells 
Stable CHO-KI cell lines expressing DSTE, wt PrP or mock were isolated by 
clonal selection in media containing 0.25 mg/ml Zeocin (Invitrogen, Carlsbad, 
CA, USA). Cell lines expressing similar levels of PrP were selected for this study.  
Cells were seeded in 24-well plates at 2x104 cells per well 24 h before treatment 
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with 1.5 mM hydrogen peroxide (Sigma) in serum-free media for 5 h. Cell viability 
was assessed by staining with 3 µM propidium iodide (PI) and Hoechst 5 µM 
(Molecular Probes) 15 min prior to collecting images from live cells. 
 
3.16 TUNEL IHC of murine brains 
Terminal UTP-mediated nick end-labeling (TUNEL) was performed using the 
Apoptag Kit (Chemicon, Billerica, MA, USA) according to the guidelines of the 
manufacturer. Half-brains were immersion-fixed in 10% formalin for 3 days 
before being embedded in paraffin, cut into 8 µm sections, and mounted on glass 
slides (Superfrost/Plus, Fisher Scientific). Sections were deparafinized in xylelne 
and were rehydrated by emerging slides through serial grades of ethanol from 
100% - 50%, and then rinsing in H2O. Sections were then quenched with 0.3% 
hydrogen peroxide for 30 min, at RT, in the dark. Sections were washed in PBS 
with 0.05% Tween 20 (PBST) 3 times for 3 min each. Sections were treated with 
20 µg/ml PK (Invitrogen) in PBS at RT for 30 min. Slides were washed as 
described above and then covered with equilibration buffe r (for 10 min at RT, 
followed by incubation with terminal deoxynucleotide transferase (TdT) in 
reaction buffer (3:7) at 37 °C in a hydration box for 1 h. The enzyme labeling was 
stopped with pre-warmed stop/wash buffer (stock:water, 1:35) at 37 °C for 40 
min. Sections were washed and then incubated with anti-digoxigenin antibody at 
RT for 30 min. Sections were washed again and developed with 
diaminobenzidine (DAB, Invitrogen) for 12 min at RT, then washed twice with 
PBST and once with PBS prior to counterstaining  with Methyl Green (Vector, 
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Burlingame, CA, USA) at 55 °C for 10 min. Slides were washed once in PBS and 
twice in H2O before a 5-second stain in eosin (Fisher Scientific). Then slides 
were dehydrated by taking through a series of graded alcohols (50% -100%) with 
changes every 5 min followed by to two 5 min incubations in xylene (Fisher 
Scientific). Coverslips were mounted on slides with Permount (Fisher Scientific). 
TUNEL-positive nuclei, which are dark reddish-brown and spherical, were 
counted in the same location of cerebellum in each brain within a defined area 
using a Microbright field measurement grid and averaged. At least three coronal 
brain sections with similar bregma were quantified form at least three mice per 
line.  
 
3.17 Activated caspase-3 IHC  
Paraffin-embedded coronal brain sections were prepared as described above  
(3.16). Before staining, sections were deparaffinized, rehydrated, and 
endogenous peroxidases blocked in the same way as performed for TUNEL 
staining (3.16). For antigen retrieval, slides were submerged in 1 mM EDTA 
(pH 8) in a closed container and microwaved to reach and hold a temperature of 
95 °C for 15 min; the temperature was checked every 5 min. Sections were 
allowed to cool to RT for 30 min, then washed in water once and PBST twice, 
each for 3 min. Non-specific antibody binding was blocked with 5% normal goat 
serum (NGS) in PBST for 30 min at RT. Sections were incubated with the 
primary antibody, anti-activated caspase-3 (9661, Cell Signaling), was diluted 
1:500 in 5% NGS/PBST overnight at 4 °C. The sections were washed in PBST, 
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3 ´ 3 min, and incubated with biotinylated secondary goat anti-rabbit (Vector) in 
5% NGS/PBST for 30 min at RT. Afterwards, slides were incubated with 1% ABC 
mixture (Vector Laboratories) for 30 min at RT, washed with PBS and stained 
with the DAB chromagen according to the manufacturer’s protocol and stopped 
by placing slides under running tap water then counter stained with methyl green, 
gradually dehydrated and coverslipped in Permount (Fisher Scientific). 
 
3.18 8-hydroxy-2-deoxyguanosine (8-OHdG) IHC 
8-OHdG is a well recognized ROS marker which has been linked with oxidative 
damage and neurodegeneration in the brain (Floyd & Carney, 1992; Won et al., 
1999). 8 µm coronal brain sections were cut from paraffin embedded brains and 
transferred to glass slides (Superfrost, Fisher Scientific). Sections were 
deparaffinized, rehydrated and rinsed in H2O as described above (3.16). Antigen 
retrieval was performed by incubating slides for 5 min in 10 mM citrate buffer pH 
6.4. Sections were then sequentially incubated with a blocking buffer containing 
5% mixed NGS and rabbit sera (1:1), goat anti-mouse IgG anti-Fc F(ab’)2 
fragment (Covalab, Villeurebanne, France) at 1:5,000 and 20 mM L-lysine in PBS 
to block endogonous IgG and other non-specific interactions. After washing with 
PBS, brain sections were incubated with primary mouse monoclonal IgG against 
8-OHdG at 1:200 (Clone 4E9, Trevigen, Gaithersburg, MD, USA) for overnight at  
4 °C, then washed with 3 times with PBS and incubated with biotinylated goat 
anti-mouse IgG (Fc) (Vector Laboratories, 1:200). Then treated with the ABC Kit 
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and developed with DAB before dehydrating and mounting slides with Permount 
as described above (3.16).  
 
3.19 Detection of PrPSc by IHC 
PrPSc was detected by IHC treatment with formic acid as previously described 
(Kitamoto et al., 1987). Half-brains were fixed in 10% buffered formalin (Fisher 
Scientific) for 5 days, processed, and embedded in paraffin according to standard 
procedures. Sections 8 µm thick were cut and mounted on glass slides 
(Superfrost Plus, Fisher Scientific) and dried overnight. Tissues were 
deparaffinized by heating at 60 °C for 30 min followed by two changes of xylene 
for 5 min each and rehydrated in graded alcohols from 100-50%. After rinsing 
with H20 endogenous peroxidases were blocked with 3% hydrogen peroxide in 
methanol for 10 min at RT. Tissue sections were washed in water and then 
autoclaved for 5 min in 10 mM sodium citrate buffer, pH 6.0 at 121 °C and cooled 
for 30 min after removal from the autoclave. The sections were then treated with 
90% formic acid for 2 min exactly at RT, and washed for 10 min in a constant 
flow of H2O. Sections were then washed with PBST 3 times for 3 min (all 
additional washing steps performed the same). Non-specific antibody binding 
was blocked with 5% NGS in PBST for 30 min at RT. Sections were incubated 
with primary antibody 13A5 at 1:500 in PBST with 5% NGS for overnight at 4 °C. 
After which sections were washed and incubated with HRP-conjugated 
secondary anti-mouse (Invitrogen) at 1:5,000 in PBST for 1 h at RT.  After 
washing, the HRP reactivity was detected with DAB, dehydrated. Sections were 
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briefly washed twice in PBST and once in PBS and then were counterstained for 
1 minute in hematoxylin (Fisher Scientific).   
 
3.20 Internucleosomal DNA-fragmentation analysis  
Internucleosomal DNA-fragmentation or DNA-laddering is recognized as a 
hallmark of apoptosis (Kerr et al., 1972). To distinguish fragmentation of DNA 
that occurs from necrotic processes (smear) rather apoptotic ones (laddering) it 
is import to validate the observations made by TUNEL to rule out necrotic 
mechanisms (Stadelmann &  Lassmann, 2000). Brain homogenates that had 
been prepared as described above (3.6) were used to extract DNA with the 
Wizard Genomic Purification Kit (Promega, Madison, WI, USA) according to the 
manufacturer’s instructions. Extracted DNA was normalized according to 
standard spectrometric measurement at 260 nm which had been corrected by 
the 280 nm extinction. Purified DNA samples were subject to  a sensitive 
detection method for DNA-laddering by ligation-mediated PCR (Staley et al., 
1997) with the LM-PCR kit (Maxim Biotech, South San Francisco, CA, USA) 
performed according to the manufacturer’s instructions. Briefly, normalized DNA 
from cerebellar brain homogenates was ligated to adaptors and then amplified by 
PCR. Adapter oligonuceotides (kit) were ligated to terminally available ends of 
100 ng extracted DNA overnight at 16 °C. 5 ng DNA was used as a template for 
the PCR with primers (kit) complementary to the ligated adapters and 
amplification was performed for 15 cycles according to the guidelines of the 
manufacturer. To control for the template concentration in the PCR, 
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Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were included 
instead of adaptor primers in a parallel PCR. Samples were then resolved by gel 
electrophoresis and stained with SYBR green I (Molecular Probes, Eugene, OR, 
USA) at 1:10,000 in H20 for 10 min in the dark followed by rinsing for 10 min in 
H2O and visualized with an ultraviolet transluminator. 
 
3.21 KA treatment and TUNEL analysis of transgenic mice 
Six to nine week old mice were treated with subcutaneous injections of 10 mg/ml 
kainic acid (KA) prepared in PBS (25–30 mg/kg) and sacrificed 24 h after the 
onset of intermittent but generalized tonic-clonic seizures which appeared in 
different degrees and extents among the various lines of mice compared. 
Untreated mice served as controls and showed no seizure activity or cell death. 
TUNEL was performed on frozen coronal brain sections using the In Situ Cell 
Death Detection kit (Roche) according to the manufacturer’s protocol and 
coverslips applied with VECTASHIELD mounting medium containing PI as 
nuclear counter stain (Vector Laboratories, Burlingame, CA, USA). 
 
3.22 KA treatment and TUNEL analysis of primary cerebellar granule cell 
neurons 
Primary cultures from the cerebellum were prepared from 7-day-old mice.  After 
decapitation brains were quickly removed and placed in ice cold dissection 
solution containing 8 g/l NaCl, 0.3 g/l KCl, 0.5 g/l NaH2PO4, 0.25 g/l KH2PO4, 4 
mg/ml NaHCO3, 2 g/l glucose. All further steps were performed on ice unless 
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stated otherwise. Cerebelli were dissected, the meninges removed and 
transferred to a solution with Hank’s balanced salt solution (BSS) containing 20% 
FBS then further transferred to serum free Hank’s BSS, minced into ~1 mm3 
sections and incubated for 5 min at 37 °C in 0.5 mg/ml trypsin (Invitrogen). After 
quenching the reaction by addition of FBS to a final concentration of 10%, the 
tissue was washed 3 times in Hank’s BSS by letting tissue settle and aspirating 
off the supernatant. The tissue was then resuspended in the dissociation solution 
containing Hank’s BSS, 12 mM MgCl2, 0.02 mg/ml DNase I (Sigma) and single 
cell suspensions prepared by trituration through several fire-polished glass 
Pasteur pipettes (Fisher Scientific) of decreasing tip diameters. Cell suspensions 
were then washed 3 times with Hank’s BSS with 20% FBS. An aliquot of cells 
was then taken, from which the proportion of viable cells was determined 
(typically over 75%) by staining with trypan blue (Sigma) and visualizing with a 
hematocytometer under a light microscope.  After counting, cells were 
resuspended in the appropriate volume of culturing media consisting of minimal 
essential medium, 10% FBS (Invitrogen), 2% B-27 (Invitrogen), 0.025 mg/ml 
insulin, 0.1 mg/ml transferrin, 5 mg/ml glucose and 2 mM glutamine that had 
been preequilibrated at 37 °C with 5% CO2 and plated at a density 1x105 per 
15 mm well of a 24 well plate coated with ploy-D-lysine and laminin coverslips 
(BD-Biosciences). 24 h after plating cells , Arabidonase C (Sigma) was added to 
a final concentration of 4 µM to suppress non-neuronal proliferation. After 72 h in 
vitro, cells were treated for 48 h with 100 mM KA, prior to fixation and TUNEL-
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staining was performed as described above (3.12) with the In Situ Death 
Detection Kit (Roche). 
 
3.23 Image and data analysis 
Fluorescent microgarphs were captured with an inverted microscope, Nikon TE-
200 (Melville, NY, USA) equipped with a cooled CCD Retiga 900 (QImaging, 
Surrey, BC, Canada) and excitation and emission filters corresponding to DAPI, 
fluorescein or Texas Red were used (Chroma, Rockingham, VT, USA). 
Monochrome images were acquired with the software Image Pro 4.5 at 8 bit 
resolution (Media Cybernetics, Bethesda, MD, USA).  
Bright field microscopy was performed using the Leica DM/IRB microscope and 
imaging using a Spot Flex digital camera and Spot Advanced software. 
All images taken part of the same experiment were acquired with the same 
exposure parameters. Monochrome images, part of multi-channel fluorescent 
sets were colored according to their original excitation wavelength and merged 
for further quantification.  
Statistical analysis was performed with Prism 4 (Graph Pad, San Diego, CA, 
USA). For pair wise comparisons T-Test were used to asses significance set to 
P<0.05 in all cases. For comparison of multiple data sets ANOVA was used to 
asses the significance of the data set. For post hoc data analysis comparing the 
significance of each pair within data set with more than three data groups, 
Turkey’s multi comparison test was used. For non-parametric pair wise 
comparison Fisher’s exact test was used. 
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Densitometric quantification of digitalized autoradiographs was performed with 
Photoshop 7 (Adobe, San Francisco, CA, USA) by determining the average 
pixels of a given band of interest corrected for the background. 
 
Presented data such as autoradiographs, Western blots and micrographs were 
all edited in Photoshop 7 by only applying the brightness, contrast and cropping 
to whole image or in case of data consisting of multiple images the same   
modifications were equally applied to the entire set acquired from one 
experiment.  
 
3.24 Multi-sequence alignment and dot-plot analysis 
The open reading frames of PrP were retrieved from the SwissProt data base in 
FASTA format and aligned with the ClustalW multi-alignment program 
(Thompson et al., 1994) found at http://www.ebi.ac.uk/Tools/clustalw/ with the 
following parameters: BLOSUM 30 matrix series, a gap opening penalty of 10 
residues, a gap separation penalty of 4 and gap extension penalty of 0.2. 
Dot plot analysis was performed with Vector NTI 6.0 (Invitrogen) with a window 
set to 15 and a stringency set to 11 (73%) with human PrP amino acid sequence 
probed against the turtle sequence. 
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4. Results 
4.1 Evolutionary analysis of topogenic domains of PrP 
Multi-sequence alignments can be helpful to highlight conserved domains that 
may be important for protein structure and/or its corresponding function. It is 
generally assumed that conservation of domains is an indication of selection 
pressure imposed on that particular domain resulting in no or few amino acid 
changes (Graur &  Li, 2000).  
Previous multi-sequence analysis of mammalian PrP has demonstrated the high 
degree of conservation (van Rheede et al., 2003). Nevertheless, further multi-
sequence analysis was performed in this study with emphasis on the topogenic 
domains. Sequence analysis was performed by multi-sequence alignment of not 
too distant species to determine if topogenic STE and TM domains of PrP are 
subject to evolutionary conservation and if the capacity of PrP to be made in 
multiple topological isoforms bears weight on organismal selection pressure. A 
multi-sequence alignment was performed with six mammalian and one reptile 
sequence using the ClustalW algorithm which highlighted several conserved 
segments of PrP including STE and TM domains (Figure 5A). Further sequence 
analysis was performed by dot plot comparing human and turtle amino acid 
residues with the window set to 15 residues the stringency set to 11 only STE 
and TM domains were highlighted (Figure 6A).  In conjunction with the notion that 
single point mutations in these domains can dramatically alter the ratio of 
expressed topological forms (Kim &  Hegde, 2002) suggest that the capacity of 
PrPC to be expressed in multiple topological forms has been maintained 
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throughout vertebrate evolution. However the detection of PrP C under normal 
physiological conditions has been limited to SecPrP and its truncated form 
(Vincent et al., 2001) and it remains unexplored if the physiological relevance of 
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4.2 PrPC is expressed as both CtmPrP and SecPrP under non-pathologic 
conditions in vivo 
To test the hypothesis that PrP C may consist of multiple topological isoforms, 
brains of wt PrP expressing mice were analyzed by the topological and 
conformational assays. 
The detection of topological forms of PrP has been previously established 
(Hegde et al., 1998a) and is based on the accessibility of membrane shielded 
PrP domains to limited proteolysis with proteinase K (PK) in the absence of any 
detergents (Figure 3A). Additionally, it has been shown CtmPrP is more protease 
resistant compared to SecPrP in the presence of non-denaturing detergent 
therefore displaying conformational variations among the two topological forms 
(Figure 3B). 
Expression of CtmPrP and SecPrP was examined in brain homogenates of 
asymptomatic transgenic (Tg) mice overexpressing wt Syrian hamster PrP 
(SHaPrP) on a Prnp-/- background, designated Tg(SHaPrP) mice, by both 
topological and conformational analysis. Tg(ShaPrP) mice were compared to Tg 
Legend Figure 5. In silicio analysis of topogenic domains. (A) The conservation of PrP 
domains was assessed by performing multi-sequence alignments of 7 vertebrate amino acid 
sequences with human, mouse, Syrian hamster, cat, sheep, bovine and turtle with Clustal W 
(Thompson et al., 1994) as described under Material and Methods. Conserved residues are 
denoted by an asterisk or red marked text; conservative substitutions are denoted by a colon.  
STE and TM domains are marked by a frame.  (B) Selection pressure on STE and TM domain 
endures thorough out vertebrate evolution. Dot plot analysis of human PrP and turtle PrP 
amino acid sequences as described under Material and Methods. With the given window of 
residues and stringency the STE and TM domains were revealed to be the most conserved 
domains within PrP.  
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mice expressing a mutant that favors either CtmPrP expression as a result of 
mutations (K110I, H111I) in the topogenic STE domain, termed 
Tg(SHaPrP,KH®II) mice, or compared to a mutant that is predominantly 
expressed in the SecPrP form as a result of a deletion of the STE domain D104-
113, termed Tg(SHaPrPDSTE) mice (Figure 6A; Yost et al., 1990; Hegde et al., 
1998a). 
To increase the likelihood of detecting CtmPrP, the topological and conformational 
analyses were performed with whole brain homogenates rather than with ER-
derived microsomal membranes (Hegde et al., 1998a; Stewart et al., 2005), as it 
represents only 1-5% of the total expressed PrP. Upon overexposure of the 
Western-blots, CtmPrP was detected in the brains of Tg(SHaPrP) mice and at 
much higher levels in Tg(SHaPrP,KH®II) mice (Figure 6B, black arrowhead). 
SecPrP and C1 were detected in all Tg mice (Figure 6B, white arrowheads). In no 
instance could NtmPrP be detected.  
To substantiate the physiological relevance of the findings in Tg(SHaPrP) mice 
the occurrence of CtmPrP and SecPrP were further analyzed in brains of non-Tg wt 
mice. With further enhancements to the detection method by immunoprecipitation 
of samples that were processed by the topological assay CtmPrP was detected in 
non-Tg wt FVB mice (Figure 6C, black arrowhead), corroborating the findings in 
Tg(SHaPrP) mice and excluding the likelihood that the detection of CtmPrP in 
Tg(SHaPrP) mice is a mere result of overexpression. Therefore the detection of 
CtmPrP and SecPrP in the healthy murine brains expressing wt PrPC provides a 
line of evidence in support of the proposed hypothesis. 
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4.3 SecPrP and CtmPrP are recognized as physiologically folded forms 
Proteins that fail to pass the quality control machinery due to misfolding are 
subject to the endoplasmic reticulum (ER)-associated degradation (ERAD), 
which involves retrotranslocation to the cytoplasm and degradation by the 
ubiquitin proteasome system. Misfolded proteins are initially retained in the ER 
with untrimmed mannose units until being transported to the cytoplasm where 
Legend Figure 6 Analysis of PrP topology in vivo. (A) Schematic diagram of topogenic PrP 
domains. Two mutants, KH®II and DSTE, were chosen that favor expression in the CtmPrP 
and SecPrP form, respectively. SS, N-terminal signal sequence; STE, stop-transfer-effector 
domain; TM, transmembrane domain; CHO, N-linked glycosylation sites; GPI, glycolipidation 
sequence. Amino acid numbering refers to the SHaPrP sequence. (B) Wild-type PrPC is 
expressed as CtmPrP and SecPrP. Topological (lanes 2, 5 and 8) and conformational (lanes 3, 6 
and 9) analyses of PrP expressed in Tg(SHaPrP,KH® II), Tg(SHaPrP) and Tg(SHaPrP,DSTE) 
mice, as indicated. Brain homogenates were left untreated (lanes 1, 4, 7) or digested with PK 
(0.25 mg/ml) in the absence (lanes 2, 5 and 8) or presence (lanes 3, 6 and 9) of Triton-X100 
(det) for 60 min at 0 °C. Samples were deglycosylated prior to Western-blotting with anti-
SHaPrP 13A5 and anti-GRP94 (control for vesicle integrity and loading). Black arrowhead 
indicates CtmPrP; white arrowhead depicts SecPrP or full-length PrP in untreated samples; 
asterisk denotes truncated PrP, termed C1. (C) CtmPrP and SecPrP are detected in non-Tg wt 
mice (lane 4). Brain homogenates from indicated mice were processed by the topological 
assay, deglycosylated, immunoprecipitated, and PrP was detected by Western-blotting with 
Fab’2 D18 which recognizes mouse PrP with a higher affinity than SHaPrP therefore SHa 
controls are underrepresented (lanes 1-3). Tg mice overexpressing mouse PrP (MoPrP) to a 
similar extent than Tg(SHaPrP) mice were used to account for the difference in antibody 
affinity. Rabbit IgG heavey chain was probed to normalize loading. Black arrowhead indicates 
CtmPrP; white arrowhead depicts SecPrP; asterisk shows truncated PrP forms C1 and C2. (D) 
Mature CtmPrP is expressed in Tg(SHaPrP) mice. Brain homogenates were subject to the 
topological assay, then left untreated (lane 1), treated with EndoH (lane 2) or treated with 
PNGaseF (lane 3). Anti-TRAPa is a control for EndoH treatment; GRP94 is a control for 
loading. Comparing amounts of deglycosylated CtmPrP was used to asses the fraction of 
matured chains, revealing that CtmPrP remains mostly resistant to EndoH treatment. 
Glycosylation is indicated by + or -. Black arrowhead indicates deglycosylated CtmPrP. 
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glycans are removed prior to degradation by UPR (Ellgaard et al., 1999). 
Therefore, PrP molecules targeted for degradation are expected to show either 
an increase in mannose-containing glycans or completely deglycosylated chains. 
To determine if the CtmPrP molecules detected in Tg(SHaPrP) brains were bona 
fide folded forms or if they were misfolded and destined for degradation the 
maturation of glycans was probed.   
Previous studies have shown mutants favoring the expression of CtmPrP mature 
to a post-ER compartment in some cases (Hegde et al., 1998a; Stewart & Harris, 
2005). However, these analyses were performed with untreated lysates and 
therefore maturation could not be attributed specifically to the subfraction of 
CtmPrP. To overcome this limitation and determine the maturation of the fraction 
of CtmPrP detected in Tg(SHaPrP) mice, the glycosylation maturation of brain 
lysates that had been processed by the topological assay followed by treatment 
with either Endoglycosidase H (Endo H), which deglycosylates immature N-
linked glycans, or by PNGase F, which deglycosylates all N-linked glycans was 
analyzed. To control for Endo H activity a known ER glycoprotein, TRAPa was 
analyzed in parallel. Most of the detected PK-resistant CtmPrP molecules 
appeared to be resistant to Endo H treatment and sensitive to PNGase F 
treatment (Figure 6D), suggesting that CtmPrP had matured to a post-ER 
compartment. SecPrP was equally Endo H resistant and appeared 
indistinguishable from CtmPrP with respect to maturation. Taken together, the 
data suggest both CtmPrP and SecPrP are topological isoforms of PrPC and are 
both processed by the folding machinery of the ER in a similar fashion. 
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4.4 Pathologic apoptosis results from CtmPrP expression 
Initial evidence suggests PrPC may naturally consist of both CtmPrP and SecPrP 
therefore it was next examined if each isoform exhibited independent functions. 
The physiologic impact and cellular response of CtmPrP and SecPrP expression 
were investigated by taking advantage of mutations biasing the fraction of each 
isoform, which enabled me to segregate and amplify the function attributed to 
each isoform upon which the activity of each isoform could be assessed in non-
Tg wt mice. 
Increased expression of CtmPrP has been associated with both transmissible and 
some genetic prion diseases (Hegde et al., 1998a; Hegde et al., 1999). However, 
the causative mechanisms underlying CtmPrP mediated disease and its potential 
cellular function remains unclear. The potential neurotoxic gain-of-function 
associated with CtmPrP expression was investigated in Tg mice. 
Tg(SHaPrP,KH®II) mice develop ataxia at ~90 days of age and show profound 
astrogliosis and vacuolation which are common neuropathological features also 
observed in other prion diseases (Hegde et al., 1998a). Upon neuropathologic 
analysis, neuronal loss and pyknotic nuclei were evident in the granule cell layer 
(GCL) of the cerebellum (data not shown), raising the possibility of apoptotic cell 
loss. Using terminal dUTP nick end-labeling (TUNEL) to evaluate apoptosis, 
brains of symptomatic Tg(SHaPrP,KH®II) mice were examined and TUNEL-
positive (+) cells were detected throughout the brain, however extensive levels 
were only observed in the cerebellum (Figure 7A). Quantitative analysis of 
TUNEL+ cells in the cerebellum was performed.  As controls, age-matched 
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Tg(SHaPrP) and Tg(SHaPrP, DSTE) mice were analyzed, which expressed total 
PrP at comparable levels in all Tg lines (Figure 7C). Tg(SHaPrP,KH®II) mice 
displayed increased TUNEL+ nuclei in the GCL of the cerebellum (Figure 7B). 
Quantitative analysis revealed ~50-fold more TUNEL+ nuclei in 
Tg(SHaPrP,KH®II) mice compared to Tg(SHaPrP) and Tg(SHaPrP, DSTE) mice 
(Figure 7D). Prnp-/- mice also showed no abnormal cell death (data not shown), 
excluding the likelihood that apoptosis is due to loss of PrP C function. To confirm 
nuclear fragmentation resulted from apoptosis, brains were further analyzed for 
internucleosomal DNA-fragmentation, a hallmark of apoptosis (Kerr et al., 1972). 
Higher levels of internucleosomal DNA-fragmentation was detected in 
Tg(SHaPrP,KH®II) mice compared to Tg(SHaPrP,DSTE) and Tg(SHaPrP) mice 
(Figure 7E) which appears consistent with the observation made by TUNEL 
analysis. Together, these findings suggest that neurodegeneration observed in 
Tg(SHaPrP,KH®II) mice occurs through apoptosis and concomitant loss of 
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4.5 Physiologic apoptosis as a result of CtmPrP expression 
Systematic analysis for apoptosis was also performed on other brain regions 
from Tg(SHaPrP,KH®II), Tg(SHaPrP,DSTE), Tg(SHaPrP), non-Tg wt and Prnp-/- 
mice. Surprisingly, significantly more TUNEL+ cells (~3-fold) was observed in the 
subventicular zone (SVZ) and subependyma (SE) of Tg(SHaPrP,KH®II), 
Tg(SHaPrP) and non-Tg wt mice, compared to Tg(SHaPrP,DSTE) mice and 
Prnp-/- mice (Figure 8E and F). Considering that both Tg(SHaPrP,DSTE) and 
Prnp-/- mice displayed similar counts in the SVZ and SE indicates that the 
reduction of TUNEL+ cells is not a consequence of SecPrP expression and argues 
lack of CtmPrP expression is the proximal cause for the reduced apoptosis 
 
Legend Figure 7. Analysis of CtmPrP-mediated apoptosis in vivo. (A) Coronal brain 
sections from Tg(SHaPrP, KH®II) mice were evaluated at ~90 days of age by TUNEL. 
TUNEL+ cells are shown from representative fields in the cerebellum (bottom left) and seven 
fields from a single brain section encompassing the hippocampus. Hp=hippocampus, 
Th=thalamus, Hy=hypothalamus, NC=neocortex, and Zl=zona incerta. Scale bars, 25 µm. (B) 
Cerebellar brain sections (coronal) from Tg(SHaPrP,KH® II), Tg(SHaPrP), and 
Tg(SHaPrP,DSTE), mice were evaluated at ~90 days of age by TUNEL. Images displayed are 
from representative matched fields with similar bregma. Arrowheads point to TUNEL+ nuclei. 
Scale bars, 25 µm. (C) Western-blotting of brain homogenates shows that all Tg mice 
expressed similar levels of PrPC, normalized against GRP94. Under these conditions PrPC 
from different Tg mice appears similar. (D) Quantitative analysis in the cerebella of the Tg 
mice indicates significantly greater TUNEL+ cells in Tg(SHaPrP,KH® II) mice. Mean, SEM, 
n=7, one-way ANOVA (P>0.0001), post-hoc Turkey multiple comparison test (**, P>0.001).  
(E) DNA was isolated from brains of CtmPrP-expressing mice and analyzed for 
internucleosomal DNA-fragmentation. GAPDH levels were assessed to control for amount of 
genomic DNA. 
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observed, suggesting the apoptosis observed in the SVZ and SE of non-Tg wt 
mice is likely associated with the expression of CtmPrP. The SVZ and SE are well 
characterized stem cell niches, also with the highest densities of physiologic 
apoptosis in the murine brain which has been attributed to the loss of progenitor 
cells that fail to establish a niche during maturation (Biebl et al., 2000). Taken 
together, the data presented here provide evidence CtmPrP may have a normal 
physiologic role triggering apoptosis in the SVZ and SE as part of the natural 






Legend Figure 8. CtmPrP dependent-apoptosis in neurogenic brain regions. (A) The 
impact of CtmPrP expression on physiological apoptosis was assessed in murine brains by 
quantification of TUNEL+ cells in the subventricular zone of Tg(SHaPrP,KH® II), Tg(SHaPrP), 
wt and Tg(SHaPrP,DSTE) and Prnp-/- mice. Mean, SEM, n£9, post-hoc Turkey multiple 
comparison test: *, P>0.01 for any pair among the two groups demarked by brackets. (B) 
Quantification of TUNEL+ cells in the subeppendyma for the same lines described in A. Mean, 
SEM, n£9, post-hoc Turkey multiple comparison test: *, P>0.01 for any pair among the two 
groups demarked by brackets. 
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4.6 Neurodegeneration and CtmPrP induction in PrPC overexpressing 
Tg(tTA:mPrP) mice 
An alternative approach was sought to demonstrate CtmPrP mediated apoptosis 
and neurodegeneration in the absence of any mutations to rule out a contribution 
of the mutation to the phenotype itself. Previous studies in Tg mice have 
revealed that the relative amount of CtmPrP increases with the expression level 
(Hegde et al., 1998a). Therefore it was plausible that extensive overexpression of 
wt PrP could facilitate increased production of CtmPrP. To avoid embryonic 
lethality which has been described when overexpressing PrP (Tremblay et al., 
1998) a reverse-tetracycline tissue specific inducible Tg model system was 
employed (Tremblay et al., 1998), termed Tg(tTA:mPrP) mice. 
 
4.6.1 Neurodegeneration and apoptosis in Tg(tTA:mPrP) mice 
At postnatal day 21 (P21), dox was withdrawn and the mice were weaned. Within 
three to four weeks, most Tg(tTA:mPrP) mice deve lop severe ataxia and circling 
(Figure 9A), at which time they were sacrificed for neuropathologic analysis. 
Postmortem histological examination of brain sections showed loss of grey 
matter with the most extensive degeneration observed in the cerebellum (Figure 
9B, left panel and data not shown). Numerous pyknotic nuclei were observed 
throughout the brain, most extensively in the granule cell layer of the cerebellum 
indicating a possible apoptotic mode of cell death (Figure 9B, left panel) as seen 
before in Tg(SHaPrP,KH®II) mice (Figure 7B). Further analysis on the 
cerebellum was performed by TUNEL to identify apoptotic cells. Thousands of 
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TUNEL-positive cells were identified in the granule cell layer (Figure. 9C, left 
panel) with many cells in the early to mid-apoptotic stage evident by the degree 
of nuclear condensation in cells staining positive for activated caspase-3 (Figure 
9D, left panel). 
To understand fur ther the development of disease, the level of cell death was 
analyzed by TUNEL on a weekly basis after PrP C induction at P21. A steady rise 
in the number of TUNEL+ cells in the first two weeks was observed, with a 
drastic increase in the third week (Figure. 9E), which correlated with the 
development of clinical symptoms. Cerebellar DNA was further analyzed for 
internucleosomal DNA-fragmentation. DNA extracts were analyzed at 0, 7, 14 
and 21 days after PrP induction. Initially, little DNA-laddering was detected, but a 
substantial increase was observed within three weeks post induction (Figure. 
9F). These data agree well with observations made by TUNEL-staining 
suggesting that apoptosis is the key mechanism of cell death and 
neurodegeneration in these mice. 
To control for the specificity of cell death by PrP, Tg(tTA:mPrP) mice were also 
kept on dox throughout the duration of all experiments presented here (Figure 
9A–F). Further, to rule out any pleiotropic effects of dox administration, Tg(mPrP) 
mice that constitutively express PrP were used as controls (Figure 9A–F) and 
were treated with dox in the same manner as the experimental animals. In all 
cases, control animals remained healthy and showed no signs of 
neurodegeneration (Figure 9A–F), indicating that the observed 
neurodegeneration is related to PrPC expression. Therefore high levels of PrPC 
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4.6.2 Dramatic CtmPrP expression in brains of Tg(tTA:mPrP) mice 
The expression level of Tg(tTA:mPrP) mice in comparison to Tg(mPrP) mice and 
wt mice was determined by Western-blotting of brain homogenates. 
Tg(tTA:mPrP) mice exhibit ~12-16 fold overexpression compared to wt mice and 
~4 fold compared to Tg(mPrP) mice (Figure 10A). Brain homogenates were 
further analyzed by the topological and conformational assays. High levels of 
CtmPrP were detected in Tg(tTA:mPrP)  mice whereas predominantly SecPrP and 
its N-terminally cleaved form, termed C1 (Vincent et al., 2001), were detected in 
Legend Figure 9. Neurodegenerative disease in inducible Tg(tTA:mPrP) mice 
overexpressing PrPC. (A)  Tg(tTA:mPrP) mice were administered dox until postnatal (P) day 
21 (open circles, n=27) or maintained on dox throughout the experiment (closed circles, n=14) 
and compared to Tg(mPrP) mice treated with dox the same way as Tg(tTA:mPrP) mice (open 
squares, n=14). Surviving mice were all sacrificed at approximately 600 days. (B) 
Histopathology in  Tg(tTA:mPrP)  (left) and Tg(mPrP) (center) were withdrawn from dox at 
P21 (left), or Tg(tTA:mPrP) mice were maintained on dox throughout (right). All mice were 
sacrificed at P42. Micrographs show hematoxylin and eosin (H&E) staining of formalin-fixed, 
paraffin-embedded coronal sections from the cerebellum. Scale bar is 50 µm. (C) Coronal 
sections from panel B were also stained by TUNEL (dark brown nuclei) to determine the level 
of cell death. Scale bar is 25 µm. (D) Coronal brain sections from panel B were also probed 
for activated caspase-3 (dark brown staining). The most significant caspase-3-positive cells 
are highlighted by arrows. Scale bar is 50 µm. (E) Quantification of TUNEL in the cerebellum 
from Tg(tTA:mPrP) taken off dox at P21 and sacrificed at time points P28, P35, and P42. The 
mean was derived from counting multiple cerebellar sections normalized for surface area, the 
error bars display the data range (n<6). (F) Verification of apoptosis by internucleosomal 
DNA-fragmentation analysis. DNA was extracted from brain homogenates and DNA-laddering 
was analyzed. Tg(tTA:mPrP)  were taken off dox at P21 and sacrificed at time points P28, 
P35 and P42. DNA -laddering increased substantially from brain samples taken at P42. 
Tg(mPrP) mice taken off dox at P21 and Tg(tTA:mPrP)  mice treated with dox throughout the 
experiment were also analyzed; both controls were sacrificed at age P42. GAPDH was 
probed to control for the amount of genomic DNA.  
 
4. Results  63 
Tg(mPrP) mice (Figure 10B, compare lane 2 with 5, lane 3 with 6). Thus, simply 
by overexpressing wt PrPC leads to changes in the topological isoform from 
predominantly SecPrP to CtmPrP, which consequently triggers neurodegeneration.  
To probe for differences in glycan maturation, brain samples from Tg(tTA:mPrP) 
mice taken off dox at P21 and sacrificed at P42 were subject to topological 
analysis and treated either with  PNGase F or with EndoH. SecPrP and most of 
the CtmPrP detected was glycosylated (Figure 10C; compare lanes 1 and 4) and 
remained mostly resistant to EndoH treatment (Figure 10C, compare lane 2 with 
5, lane 3 with 6), suggesting that both isoforms have passed the ER quality 
control machinery. Taken together the data suggest that overexpression of wt 
PrPC can lead to a dramatic induction of CtmPrP which leads to rapid and severe 
neurodegeneration triggered by capase-3 mediated apoptosis. 





Legend Figure 10. Overexpression of PrPC results in a disproportionate increase in 
CtmPrP expression. (A) The expression level of PrP in the cerebellum was determined at P42 
by Western-blotting of normalized brain homogenates from Tg(tTA:mPrP) taken off dox at  
P21, lanes 1, 2, 3, 4 with 10 µl, 5 µl, 2.5 µl and 1 µl loaded respectively;  Tg(mPrP) taken off 
dox at P21, lanes 5 and 6 with 10 µl and 5 µl loaded respectively; non-treated wt mice, lanes 7 
and 8 with 20 µl and 10 µl loaded respectively; Tg(tTA:mPrP) on dox, lane 9 with 10 µl and 
non-treated Prnp-/- mice, lane 10 with 10µl. Brain homogenate were resolved and probed 
against anti-PrP (D18) and anti-GRP 94 (loading control). (B) Topological and conformational 
analysis of PrPC from brains of Tg mice described in panel A. Whole brain homogenates were 
either left untreated (lanes 1, 4, 7) or digested with PK in the absence (lanes 2, 5, 8) or 
presence (lanes 3, 6 and 9) of Triton-X100 (Det). Samples were deglycosylated with PNGase 
F prior to Western-blotting with anti-PrP and anti-GRP94 (loading control). Note that the 
CtmPrP signature fragment remains protected from PK in the presence of detergent. Black 
arrowhead depicts the position of CtmPrP; white arrowhead depicts the position of SecPrP or 
full-length PrP in untreated samples. The asterisk signifies the position of the C1 proteolytic 
fragment of PrP. (C) CtmPrP maturation was investigated in Tg(tTA:mPrP) mice taken off dox 
at P21 and sacrificed at P42 by Endo H treatment. Brain homogenates were subjected to 
topological and conformational analysis as described in panel A and treated with either EndoH 
or PNGase F. Black arrowhead depicts the position of deglycosylated CtmPrP. 
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4.7 A cell culture model system:  CtmPrP triggers apoptosis in a dose-
dependent manner 
To investigate if the observed apoptosis in brains of Tg(SHaPrP,KH®II) mice 
and Tg(tTA:mPrP) mice is a direct consequence of CtmPrP expression, a cell 
culture-based assay was established. CHO-KI cells were transfected with either 
the CtmPrP-favoring mutant KH®II, the SecPrP-favoring mutant DSTE, or wt PrP. 
Western-blot analysis of cell lysates confirmed that expression levels and 
glycosylation patterns of PrP were similar (Figure 11A) in all three PrP 
transfectants. Next, topological and conformational analysis of metabolically 
labeled immunoprecipitated cell lysates were performed to determine the relative 
amount of CtmPrP expression. Quantitative analysis revealed 56%, 20% and 2% 
of CtmPrP in the KH®II, wt and DSTE transfectants, respectively (Figure 11B). 
Fixed cells were stained with an anti-PrP antibody and 4',6-diamidino-2-
phenylindole (DAPI) to identify transfected cells and analyze their respective 
morphology. In the KH®II transfectants, many cells showed condensed elliptic to 
circular soma; some wt PrP-expressing cells showed a similar cytopathic 
phenotype (Figure 11C). A proportion of the cytopathic cells displayed 
condensed or fragmented nuclei which frequently stained positive for TUNEL 
(Figure 11C) or activated caspase-3 (Figure 11C, insert). Analysis of TUNEL 
staining showed cells  expressing the KH®II mutant had significantly higher 
incidences of TUNEL+ nuclei compared to cells expressing the same level of wt 
PrP; cells expressing similar levels of the DSTE mutant had the least amount of 
TUNEL+ nuclei (Figure 11C and D). A strong correlation was identified between 
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CtmPrP levels and cell death: higher proportions of CtmPrP expression correlated 
with more TUNEL+ cells (Figure 11E), arguing that CtmPrP triggers apoptosis in a 
dose-dependent manner. Furthermore, the correlative evidence shows that wt 
PrP has the capacity to trigger cell death, dependent on its propensity to 
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4.8 Characterization of the apoptotic pathway triggered by CtmPrP: 
caspase-3 and Bax dependence 
To verify the apoptotic specificity of the TUNEL staining and determine the 
significance of the activated caspase-3 staining , KH®II-transfected cells were 
treated with AC-DEVD-FMK, an inhibitor for caspase-3. The caspase-3 inhibitor 
substantially reduced the number of TUNEL+ nuclei, in contrast to control cells 
only treated with the vehicle (Figure 12A and B). Taken together, the data 
suggest CtmPrP triggers apoptosis by a caspase-3–mediated pathway in a dose-
dependant manner.  
The involvement of the pro-apoptotic protein Bax (Oltvai et al., 1993), which has 
been implicated previously in neurodegenerative disorders (Vila et al., 2001; Lok 
& Martin, 2002), including some prion diseases (Chiesa et al., 2005) was 
 
Legend Figure 11. Analysis of CtmPrP-induced apoptosis in cultured cells. (A) Western-
blot analysis probed with anti-PrP and anti-GRP78 (loading control) shows that all 
transfectants express similar levels of PrP. (B) Topological (lanes 2, 5 and 8) and 
conformational (lanes 3, 6 and 9) analyses of CHO-KI cells expressing KH®II, wt PrP or 
DSTE were performed. Lanes 1, 4 and 7, untreated cells. White arrowhead indicates full-
length PrP (untreated) or SecPrP; black arrowhead indicates CtmPrP. CtmPrP levels are indicated 
as percentages of total full-length PrP from four determinations. (C) Analysis of apoptosis in 
PrPC mutants. CHO-KI cells were fixed 48 h after transfection with KH®II, wt or DSTE  and 
stained by DAPI (blue), TUNEL (green) and anti-PrP (red). Arrowheads depict PrP transfected 
TUNEL+ cells. Scale bar, 20 µm. Insert: activated caspase-3 (green) in KH-II transfectants 
(red) with fragmented nuclei (blue). (D) Quantitative analysis of TUNEL+ PrP transfectants 
from experiments described in C. ~200 cells were counted for each transfectant per 
experiment. 3 determinations, mean, data range, one-way ANOVA (P>0.0001), post-hoc  
Turkey multiple comparison test (P>0.001 for all pairs).  (E) CtmPrP expression triggers 
apoptosis in a dose dependant manner. The relative expression level of CtmPrP (panel B) 
plotted against the extent of apoptosis (panel E) shows a strong correlation (R2=0.9941).  
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investigated. To test if CtmPrP-triggered apoptosis occurs through a Bax-
dependent pathway, CHO-KI cells expressing the KH®II mutant were treated 
with a cell-permeable Bax-inhibiting peptide (V5, (Sawada et al., 2003)). 
Compared to control cells, a substantial reduction in TUNEL+ cells was observed 
with the Bax inhibitor (Figure 12A and B). Taken together the data suggests that 
CtmPrP may trigger apoptosis by a Bax and caspase-3 mediated pathway.  
In many instances the pro-apoptotic activity of Bax can be blocked by the 
expression of antagonizing anti-apoptotic proteins such as Bcl-2 or other 
members of the BH2 family (Oltvai et al., 1993, Shimizu et al., 1995). Hence it 
was tested if CtmPrP-mediated apoptosis could be blocked by the overexpression 
of anti-apoptotic molecules Bcl-2 or Bcl-XL. CHO-KI cells expressing either Bcl-2 
or Bcl-XL were clonally selected for high levels of expression (data not shown). 
The resulting lines were transfected with the CtmPrP-favouring KH®II mutant, and 
the effect of Bcl-2 or Bcl-XL overexpression on CtmPrP-triggered apoptosis 
assessed 48 h later by TUNEL (Figure 12C). Both Bcl-2 and Bcl-XL suppressed 
CtmPrP-mediated apoptosis, by four- and nine-fold, respectively, compared to 
mock transfected cells (Figure 12D). Hence, Bcl-2 and Bcl-XL seem to 
antagonize CtmPrP activity. Along with previous results, these findings suggest 
that CtmPrP-triggered apoptosis may involve Bax, leading to caspase-3 activation, 
and ultimately, to internucleosomal DNA-fragmentation and cell death. 
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Legend Figure 12. Analysis of the pathway of CtmPrP-induced apoptosis. (A) CtmPrP-
induced apoptosis is caspase-3 and Bax-dependent. CHO-KI cells expressing the KH®II 
mutant were either left untreated, or treated with 100 mM of the specific caspase-3 inhibitor 
(DEVD) or 100 mM of a Bax-inhibitor (V5) or the vehicle alone. Experiments were carried out 
as in panels Figure 11C. Scale bar, 50 µm. (B) Quantitative analysis of the effect of the DEVD 
and V5 on CtmPrP induced apoptosis was performed as described in Figure 11D. Mean, data 
range, paired one-tailed T-test (**, P>0.001, ***, P>0.0001). (C) CtmPrP-mediated apoptosis 
can be rescued by the overexpression of Bcl-2 and Bcl-XL. CHO-KI cell lines overexpressing 
Bcl-2 and Bcl-XL were assayed for CtmPrP-mediated apoptosis as described in Figure 11C. 
Scale bar, 50 µm. (D)  Quantitative analysis of CtmPrP induced apoptosis in cells over-
expressing Bcl-2 and Bcl-XL was performed as described in Figure 11D. Mean, data range, 
paired one-tailed T-test (***, P>0.0001). 
Figure 12 
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4.9 SecPrP protects cultured cells from ROS 
After attributing the toxic activity of PrPC to the expression of CtmPrP, it was 
examined whether SecPrP provides protection against ROS since such a function 
has been proposed for PrPC (Wong et al., 2001; Brown et al., 2002; McLennan et 
al., 2004). Clonal CHO-KI cell lines expressing either DSTE or wt PrPC at similar 
levels (Figure 13A) or a non-coding plasmid (mock) were subjected to hydrogen 
peroxide treatment, a broad inducer of ROS. Viability was evaluated by imaging 
of live cells stained with propidium iodide (PI) and Hoechst 22324 (Figure 13B). 
DSTE-expressing cells had the highest viability followed by wt PrPC-expressing 
cells. Mock transfectants in contrast showed barely any survival to the oxidative 
insult (Figure 13C). Consistent with the function proposed for PrP C it could be 
found that the protective activity against ROS is likely mediated by the SecPrP 
isoform. Therefore two distinct functions for PrPC could be shown in the same cell 
type which is likely due to activities of distinct topological isoforms. 
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4.10 SecPrP protects primary cultured neurons from ROS 
Next, it was investigated whether primary granule cell neurons (GCN) derived 
from Tg(SHaPrP,DSTE), non-Tg wt  mice and Prnp-/- mice would also reveal 
protection of SecPrP to ROS. Primary cerebellar GCNs were exposed to kainic 
acid (KA) an inducer of ROS (Wang et al., 2005) for 48 hours and analyzed for 




Legend Figure 13. Analysis of SecPrP-mediated protection from ROS in CHO-KI cells. (A) 
CHO-KI cells were stably transfected with DSTE, wt PrP and a non-coding plasmid (mock). 
Clones were selected for similar expression levels of PrP as shown by Western blot analysis 
of anti-PrP and anti-GRP78 (loading control). (B) SecPrP expression protects CHO-KI cells 
from oxidative insult. Cell lines were exposed for 5 h to hydrogen peroxide (1.5 mM) prior to 
live cell analysis. PI (red) and Hoechst (blue) staining were used to assess viability. Scale bar, 
50 µm. (C) Quantitative analysis of cellular survival of experiments from panel B expressed as 
a fraction of PI-positive to total cells. ~200 cells per experiment were counted. 3 
determinations, mean, data range, one-way ANOVA (P>0.0001), post-hoc Turkey multiple 
comparison test (P>0.001 for all pairs). 
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mice reveled the greatest protection with half the cell loss compared to cultures 
from non-Tg wt mice and cultures prepared from Prnp-/- mice showed over all the 
highest vulnerability (Figure 14B). These results are consistent with the findings 
in CHO-KI cells (Figure 13).  The data suggest SecPrP averts cell death from 
ROS. Taken together with previous results the findings provide a basis for the 






Legend Figure 14. Analysis of SecPrP-mediated protection from in primary granule cell 
neurons. (A) SecPrP protects primary cerebellar granule cell neurons (GCN) from oxidative 
insult. GCN cultures were prepared from 7-day-old Tg(SHaPrP,DSTE) mice, non-Tg wt or 
Prnp-/- and after three days of incubation were treated for 48 h with 100 µM KA, fixed,  then 
stained by TUNEL (green) and counterstained with DAPI (blue). Scale bar, 50 µm. (B)  
Quantification of ROS vulnerability in cerebellar GCNs. The ratio of TUNEL+ to total nuclei 
was determined to establish the fraction of apoptotic cells. Multiple fields per coverslip were 
randomly selected for quantification purposes. Mean, SEM, (n=3), unpaired two-tailed T-test 
(**, P>0.001) for all comparisons to Prnp-/- mice. 
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4. 11 A model system to probe both PrPC functions in vivo: kainic acid-
mediated neurodegeneration 
The results thus far suggest CtmPrP triggers apoptosis and SecPrP protects cells 
from ROS. To understand how the two isoforms interplay in vivo and to further 
substantiate the observations made in vitro, mice were subjected to KA-induced 
seizures. KA triggers excitotoxic apoptosis in the pyramidal cell layer of the 
hippocampus and also leads to increased ROS which can independently trigger 
apoptosis (Wang et al., 2005). This model system would likely enable me to test 
simultaneously the roles of CtmPrP in excito toxic apoptosis and of SecPrP in 
neuroprotection from ROS.  
Tg(SHaPrP,DSTE), Tg(SHaPrP,KH®II), Prnp-/- and non-Tg wt mice treated with 
KA were monitored and, if still alive, were sacrificed 24 h later and their brain 
tissue analyzed for neuropathologic changes. While the extent of KA-induced 
seizure activity observed was comparable among all lines investigated, the 
mortality rate and extent of neurodegeneration were vastly different. 
Tg(SHaPrP,KH®II) mice had the highest mortality rate. In contrast, none of the 
Tg(SHaPrP,DSTE) mice died in response to KA treatment (Figure 15A). Brains of 
surviving mice were examined by histological analysis (Figure 15A) and TUNEL 
(Figure 15B), which consistently identified Tg(SHaPrP,KH®II) with the highest 
incidence of TUNEL+ cells as quantified in the hippocampal CA3 region. In 
contrast, non-Tg wt mice revealed moderate numbers of TUNEL+ cells and 
Tg(SHaPrP,DSTE) mice showed few TUNEL+ cells (Figure 15C). 
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The relative contribution of CtmPrP and SecPrP levels to KA-mediated apoptosis 
was assessed by using the level of apoptosis in Prnp-/- mice as a comparative 
baseline. Hence, both topological isoforms contributed to KA-mediated 
vulnerability (Figure 15C): SecPrP-expression reduces apoptosis whereas CtmPrP-
expression enhances apoptosis. Most importantly, non-Tg wt mice displayed an 
intermediate position relative to mice favoring either CtmPrP or SecPrP expression 
in terms of both mortality (Figure 15A) and neuronal vulnerability to KA (Figure 
15C) supporting the hypothesis PrPC has the capacity to form both. Furthermore, 
the amount of cell death shows an inverse correlation to the propensity of the 
transgene to be synthesized in the SecPrP isoform (Figure 15D). Therefore, 
apoptosis can be stimulated by CtmPrP and averted by SecPrP suggesting 
 
Legend Figure 15. Analyzing the role of PrPC topology in kainic acid-mediated 
neurodegeneration. (A) Tg(SHaPrP,KH® II), Tg(SHaPrP,DSTE ), Tg(SHaPrP) and Prnp-/- 
mice were treated with a single dose of subcutaneous KA sufficient to induce intermittent 
generalized tonic-clonic seizures. Mortality within the first 24 h was determined and pathologic 
damage was rated by examining brain sections stained with hematoxylin and eosin. Damage 
in the hippocampus was rated as mild (+), moderate (++) or severe (+++). CtmPrP-expressing 
mice died at a significantly higher rate (*, P>0.01, Fisher’s exact test) than mice expressing 
SecPrP. (B) Hippocampal sections from treated mice were analyzed for apoptosis by TUNEL 
(green) and counterstained with PI (red). Mice expressing SecPrP show very little apoptosis 
compared to CtmPrP-expressing mice and Prnp-/- mice. Scale bar, 10 µm. (C) Quantitative 
analysis of apoptosis in the CA3 region. The ratio of TUNEL+ nuclei to total nuclei was used 
to determine the fraction of apoptotic cells. Mean, SEM, n£3, one-way ANOVA (P>0.0001), 
post-hoc Turkey multiple comparison test (P>0.001 for all pairs). (D) Neuroprotection is 
dependent on SecPrP expression. Protection was assessed from the data in panel C and 
plotted against the propensity of PrP to be expressed as SecPrP (Inverse fraction of CtmPrP; 
Figure 11B) shows a correlation (R2= 0.9994). (E) KA-induced ROS in the hippocampus was 
assessed by measuring MDA levels in homogenates from mice subjected to KA. Mean, SEM, 
n=6, one-way ANOVA (P>0.0001), post-hoc Turkey multiple comparison test (*, P>0.05, **, 
P>0.001). 
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neurodegeneration can result from both a loss of SecPrP function and a gain of 
CtmPrP function. 
To explore the possibility SecPrP is protecting neurons by preventing ROS 
mediated damage, hippocampal homogenates from KA-administered mice were 
analyzed for oxidative damage by measuring the amount of malondialdehyde 
(MDA). The lowest concentration of MDA was seen in Tg(SHaPrP,DSTE) mice 
(Figure 15E) with levels comparable to untreated control animals (data not 
shown). Mice bearing increased cell death revealed the highest levels of MDA 
(compare Figure 15C and E), however MDA levels in Prnp-/- and 
Tg(SHaPrP,KH®II) mice were similar indicating a reduction in ROS is a result of 
SecPrP expression and not affected by CtmPrP expression. It is should be noted 
that the difference in oxidative stress levels in the hippocampus was not 
significantly different among various untreated mouse lines (data not shown), 
therefore excluding the likelihood that these mice are not predisposed to 
increased oxidative stress levels. Furthermore, it suggests SecPrP poses a benefit 
under acute ROS conditions and appears to have little impact on ROS levels 
under normal conditions. Taken together, these results indicate SecPrP protects 
neurons from apoptosis by reducing KA-induced oxidative damage whereas 
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4.12 Probing the bifunctional hypothesis: Infectious prion disease and the 
role of topology 
Motivated by observations that both CtmPrP and SecPrP contribute to KA-mediated 
neurodegeneration, this same possibility was evaluated in mice inoculated with 
prions. 
Two lines of evidence argue CtmPrP expression is a determinant of pathogenesis 
in infectious prion disease (Hegde et al., 1999). First, the time point of disease 
onset inversely correlates with the CTM index, a measure of the absolute amount 
of CtmPrP expressed in the murine brain. Higher levels of endogenous CtmPrP at 
the time point of infection relate to shorter incubation periods. Second, upon 
infection with PrPSc, an increase in CtmPrP expression was detected. Elevation of 
CtmPrP may trigger pathogenic changes in prion disease, such as apoptosis as 
demonstrated in this study. 
To dissect the contributions of CtmPrP and SecPrP in the pathogenesis of 
infectious prion disease, Tg mice that expressed either increased CtmPrP or 
SecPrP were inoculated with hamster Sc237 prions (Hegde et al., 1999). To avoid 
interference from spontaneous neurodegeneration caused by CtmPrP expression, 
Tg mice that express CtmPrP to a lesser extent than the Tg(SHaPrP,KH®II) mice 
were used; these mice, designated Tg(SHaPrP,A117V), express PrP with an 
A117V mutation, develop spontaneous disease at ~572 days (Hegde et al., 
1998a) and clinical symptoms at ~51 days postinoculation with Sc237 prions 
(Figure 16A; Hegde et al., 1999). In contrast, Tg(SHaPrP,DSTE) mice, which 
express similar levels of PrP in the brain (Figure 16B) but do not express CtmPrP 
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(Figures 6B, 6C and 16C), show no spontaneous neurodegeneration (up to 700 
days of observation) and do not develop any symptoms until ~324 days 
postinoculation with Sc237 prions (Figure 16A; Hegde et al., 1999). In 
comparison, Tg mice expressing wt PrP at ~2-fold higher PrP levels than 
Tg(SHaPrP,A117V) and Tg(SHaPrP,DSTE) mice develop symptoms at ~55 days, 
and mice expressing wt PrP at a quarter of the expression levels develop 
symptoms at ~170 days postinoculation (Prusiner et al., 1990). The data suggest 
disease progression is accelerated in Tg(SHaPrP,A117V) mice and attenuated in 
Tg(SHaPrP,DSTE) mice, in respect to what would be expected in mice with 
similar wt PrP expression levels. Consistent with previous findings, the 
propensity of PrPC to be expressed in the CtmPrP isoform is a key determinant of 
incubation time to disease onset upon inoculation with PrPSc. It should be noted 
that Tg(SHaPrP,DSTE) mice lacking expression of CtmPrP still develop symptoms 
albeit after prolonged incubation. 
Qualitative analysis of PrPSc accumulation in the brains of these ill mice revealed 
little PK-resistant PrPSc in Tg(SHaPrP,A117V) mice but abundant PK-resistant 
PrPSc in Tg(SHaPrP,DSTE) mice (Figure 16D; Hegde et al., 1999). 
Tg(SHaPrP,A117V) mice showed abundant PrPSc deposits in the thalamus, 
hypothalamus, piriform cortex and corpus callosum. In contrast, 
Tg(SHaPrP,DSTE) mice showed PrPSc deposits through the entire brain with 
highest levels in the thalamus, midbrain, brainstem and cerebellum (Figure 17A 
and B). PrPSc accumulation in Tg(SHaPrP,A117V) mice was limited to brain 
regions close to the inoculation site as the incubation period was relatively short, 
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in comparison to Tg(SHaPrP,DSTE) mice for which sufficient time was available 
for PrPSc to spread throughout the entire brain, which is in agreement with 
previous findings that accumulation of PrPSc does not correlate with 





Legend Figure 16. Analysis of a dual role of PrPC topology in transmissible prion 
disease . (A) The propensity to generate CtmPrP dictates the time of disease onset in 
Tg(SHaPrP,A117V), n=15 and Tg(SHaPrP,DSTE), n=9 mice inoculated with Sc237 prions. (B) 
Western-blot analysis show similar PrP expression levels in the brains of Tg(SHaPrP,A117V) 
and Tg(SHaPrP,DSTE) mice. Blots were probed with anti-PrP and anti-GRP94 (loading 
control). (C) Toplogical (lanes 2 and 4) analysis of PrP in Tg(SHaPrP,A117V) and 
Tg(SHaPrP,DSTE) mice. Brain homogenates were either left untreated (lanes 1 and 3) or 
treated with PK in the absence of detergent (lanes 2 and 4). Samples were deglycosylated 
prior to Western-blotting with anti-PrP and anti-GRP94 (loading control). Black arrowhead 
indicates CtmPrP; white arrowhead indicates SecPrP; asterisk denotes position of C1. (D) PrPSc 
accumulation in the brains of Tg mice inoculated with Sc237 prions. Brain homogenates were 
left either untreated (left panel) or treated under harsh PK conditions at 0.5 mg/ml for 1 h at 
37 °C (right panel) and probed with an anti-PrP antibody by Western-blotting. 
Tg(SHaPrP,DSTE) mice show marked accumulation of PrPSc compared to 
Tg(SHaPrP,A117V) mice. 
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4.13 Gain and loss of PrPC functions: Oxidative stress and apoptosis in 
prion infected mice 
Based on the notion that both apoptosis (Giese et al., 1995; Liberski et al., 2004) 
and oxidative stress (Milhavet et al., 2000; Wong et al., 2001) occur in PrPSc-
inoculated subjects, a prediction was made that Tg(SHaPrP,DSTE) mice would 
show little apoptosis and only signs of ROS accumulation whereas 
Tg(SHaPrP,A117V)  mice would likely show both apoptosis and oxidative 
damage. Apoptosis and ROS accumulation were probed by 
immunohistochemistry with TUNEL and 8-hydroxy-2-deoxyguanosine (8-OHdG) 
respectively. In the brains of Sc237-infected Tg(SHaPrP,A117V) mice, TUNEL+ 
cells were found, with high levels in brain regions with PrPSc deposits, such as 
the thalamus (Figure 17C). Only a few TUNEL+ cells were detected in 
Tg(SHaPrP,DSTE) mice, with most abundant levels in the cerebellum (Figure 
17C and D). The data suggest apoptosis may play an important role in PrPSc-
mediated pathogenesis in Tg(SHaPrP,A117V) mice. However, the substantially 
reduced apoptosis observed in Tg(SHaPrP,DSTE) mice suggests other 
pathogenic mechanisms not associated with CtmPrP upregulation and apoptosis 
are revealed in these mice. The long incubation period in Tg(SHaPrP,DSTE) 
mice suggests that gain of CtmPrP function plays a more dominant role in prion 
pathogenesis.  
In both Tg(SHaPrP,A117V) and Tg(SHaPrP,DSTE) mice, increased levels of 
8-OHdG were observed in brain regions with the most prominent PrPSc deposits. 
For Tg(SHaPrP,A117V) mice, 8-OHdG was observed in several brain regions, 
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most extensively in the thalamus (Figure 17E and F). Increased 8-OHdG levels in 
Tg(SHaPrP,DSTE) mice were found in the thalamus, midbrain, brainstem and 
cerebellum. In summary, the data reveal that pathogenesis in Tg(SHaPrP,DSTE) 
mice have likely resulted from increased ROS which leads to neurodegeneration 
without triggering an apoptotic pathway involving chromosomal DNA-
fragmentation. In contrast Tg(SHaPrP,A117V) mice succumbed to cell loss 
resulting from both apoptotic and non-apoptotic ROS related dysfunction or loss 
of neurons. Taken together, the data suggest that upregulation of CtmPrP is not 
the sole mediator of pathogenesis. Additionally, the conversion of SecPrP to PrPSc 
appears to lead to a loss of protection from oxidative insult. 




Legend Figure 17. IHC of prion infected brains. (A and B) PrPSc staining in coronal brain 
sections from symptomatic Tg(SHaPrP,A117V) (left panel) and Tg(SHaPrP,DSTE) mice (right 
panel) inoculated with Sc237 prions. Tg(SHaPrP,A117V) mice only showed focal distribution 
of PrPSc limited to the thalamus, hypothalamus, piriform cortex and corpus callosum whereas 
Tg(SHaPrP,DSTE) mice showed diffuse deposits of PrPSc throughout the brain with high 
concentrations in the thalamus, cerebellum, midbrain and brainstem. (C and D) TUNEL 
staining in brain sections of symptomatic Tg(SHaPrP,A117V) mice show high levels of 
apoptosis in regions with abundant PrPSc. In contrast, few TUNEL+ cells are seen in 
symptomatic Tg(SHaPrP,DSTE) mice. (E and F) Oxidative stress-induced damage was 
determined by 8-OHdG staining. Tg(SHaPrP,A117V) mice (left panel) show positive nuclear 
or perinuclear staining in brain regions with increased deposits of PrPSc. Low levels of 
8-OHdG were also detected in few unaffected brain regions, including the granule cell layer of 
the cerebellum. Tg(SHaPrP,DSTE) mice (right panel) show punctuate staining in white matter 
with some nuclear staining in the thalamus and cortical regions. Representative images are 
from the thalamus (panels A, C, E) and cerebellum (panels B, D, F). Scale bar, 50 µm. 
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5. Discussion  
The physiologic function of PrPC and its role in prion disease remains unclear as 
both neuroprotective (Chiarini et al., 2002; Roucou et al., 2004) and toxic 
functions (Westaway et al., 1994; Shmerling et al., 1998; Paitel et al., 2003) have 
been described. Alongside these conflicting findings, a long-standing debate 
continues about whether prion disease pathogenesis results from a gain or a loss 
of PrPC function or both (Brown, 2005; Harris & True, 2006). The data presented 
here provide a framework describing how heterogeneity of PrPC topology can 
result in both pro- and anti-apoptotic functions and propose how both loss and 
gain of PrPC-mediated functions could  contribute to prion disease. 
 
5.1 Conservation of PrPC synthesis in  multiple topological isoforms 
It has previously been reported that PrP has been conserved throughout 
mammalian evolution (van Rheede et al., 2003) suggesting an important function 
associated with PrPC. Further sequence analysis performed in this study 
revealed topogenic STE and TM to be the most conserved domains within PrP. 
Given the notion that a single point mutation in these domains can have a 
dramatic impact on the ratio of topological isoforms (Kim & Hegde, 2002), it is 
tempting to speculate that the propensity to generate CtmPrP and SecPrP has been 
conserved which in turn indicates important physiological functions that may be 
associated with each isoform. However an alternative interpretation would be that 
the conservation of TM and STE domains is associated with a function distinct 
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from that ascribed as a topogenic determinant. Therefore the basis for the 
detected conservation awaits future determination.  
 
5.2 PrPC is synthesized as both SecPrP and CtmPrP under physiological 
conditions 
In vitro studies have demonstrated the propensity of PrPC to be expressed in 
three topological forms: SecPrP, CtmPrP and NtmPrP (Hay et al., 1987a; Hay et al., 
1987b; Hegde et al., 1998a; Stewart & Harris, 2001). Under normal physiologic 
conditions the detection of PrPC has been limited to SecPrP and its truncated form 
C1 (Vincent et al., 2000). In vivo, CtmPrP and NtmPrP have only been associated 
with pathologic conditions (Hegde et al., 1998a; Hegde et al., 1999; Risitano et 
al., 2003; Stewart et al., 2005); therefore it has been generally assumed that 
normal PrPC consists of only SecPrP. The data presented here suggests that PrPC 
is expressed as both CtmPrP and SecPrP albeit CtmPrP is expressed at very low 
levels as seen in normal non-Tg wt mice, which forms the basis for the 
hypothesis that both topological isoforms are physiologically relevant. As NtmPrP 
was not detected at any instance in brains of mice it remains unclear if this is for 
technical reasons or a result of lack of expression in the adult tissue analyzed. 
The observation that both SecPrP and CtmPrP detected in wt PrP expressing mice 
are recognized and processed by the ER-folding machinery in a similar fashion is 
in agreement with the hypothesis that both isoforms are physiologically relevant. 
However, consideration should also be given to the potential idea that escaping 
from the quality control machinery of the ER could pose a pathologic mechanism 
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inherent to some secretory proteins. And indeed there is precedence that 
unglycosylated mutant PrP can reach the plasma membrane (Korth et al., 2000) 
questioning the overall quality control fidelity attributed to PrP and raising the 
possibility that CtmPrP could also escape the quality control mechanisms. 
However, it should also be noted than in most instances pathogenic and mutant 
PrP forms are retained in ER and degraded or accumulate in the cytoplasm (Ma 
&  Lindquist, 2001; Stewart et al., 2001; Grasbon-Frodl et al., 2004). A further line 
of though raises the possibility that our understanding of the quality control 
mechanisms of the ER are limited with unique scenarios that are yet to be 
defined. In light of these views further studies will be required to substantiate the 
finding made here if the small fraction of CtmPrP detected under normal 
physiologic conditions is truly a bona fide folded isoform of PrP C. 
 
5.3 CtmPrP dependent pathophysiological apoptosis 
The detection of apoptosis in prion diseases has been described (Giese et al., 
1995; Liberski et al., 2004) however the mechanisms underlying apoptosis have 
remained unclear. Also, the expression of CtmPrP has been correlated with the 
development of neurodegeneration in genetic and infectious model systems 
(Hegde et al., 1998a; Hegde et al., 1999). The here presented results from 
transgenic mice and CHO-K1 cells suggest CtmPrP can cause neurodegeneration 
through an apoptotic pathway. Tg(SHaPrP, KH®II) mice and Tg(tTA:mPrP) mice 
show increased expression of CtmPrP and develop neurodegeneration with 
substantial loss of cerebellar granule cells. The detection of internucleosomal 
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DNA-fragmentation, pyknotic or fragmented nuclei and TUNEL+ cells along side 
with the detection of activated caspase-3 suggest cell death occurs through an 
apoptotic pathway. The contemporaneous detection of elevated CtmPrP 
expression further suggests apoptosis is likely triggered by CtmPrP expression.  
Furthermore, the lack of any mutation in Tg(tTA:mPrP) mice shows that CtmPrP 
production in Tg(SHaPrP, KH®II) mice is not just a result of the mutation itself 
and further delivers evidence that mere overexpression of PrPC can lead to 
dramatic CtmPrP upregulation and apoptosis in the cerebellum of mice. 
A direct relationship was further elucidated in cultured CHO-KI cells and a strong 
correlation was revealed demonstrating the capacity of PrP to trigger apoptosis is 
dependent on the propensity of PrP to be made in the CtmPrP isoform. The 
expression of wt PrPC also demonstrated a mild capacity to trigger cell death 
corresponding to the level of CtmPrP expression. It is likely that apoptosis 
triggered by CtmPrP is dependent on the activation of caspase-3 since both the 
activated form was detected and a significant reduction in apoptosis was 
observed by treatment with a caspase-3 inhibitor. Taken together the data 
suggests CtmPrP can trigger apoptosis in a dose dependent manner by a 
caspase-3-mediated pathway leading to cell loss and neurodegeneration. Given 
that CtmPrP has been implicated in both genetic (Hegde et al., 1998a) and 
infectious prion diseases (Hegde et al., 1999), it is likely that CtmPrP plays an 
important role contributing to neurodegeneration in these cases by triggering 
caspase-3 dependent apoptosis. 
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The implication of pro- and anti-apoptotic members of the Bcl-2 family on CtmPrP 
mediated apoptosis was investigated. The overexpression of both anti-apoptotic 
proteins Bcl-2 and Bcl-XL significantly reduced the apoptotic potential of CtmPrP. 
Moreover inhibition of Bax reduced the amount of apoptosis triggered by CtmPrP.  
Hence apoptosis triggered by CtmPrP may be Bax dependant which appears to be 
consistent with some experimental prion disease model systems which reveals at 
some instances Bax dependency (Chiesa et al., 2005; Lyahyai et al., 2006; Li et 
al., 2007). Furthermore the ascribed BH2 like OR domain of CtmPrP (LeBlanc &  
Roucou, 2003) could potentially interact with BH2 family members, since it has 
been reported that PrP can interact with Bcl-2 in a yeast two hybrid system 
(Kurschner &  Morgan, 1995, 1996). However the relevance of these findings is 
questionable as the reproduction in mammalian systems has been futile 
(Kurschner & Morgan, 1996).  
 
5.4 CtmPrP dependent physiological apoptosis 
A potential neurophysiologic role for CtmPrP mediated apoptosis was highlighted 
in the SVZ and SE by quantitative TUNEL analysis. The SVZ and SE are two 
neurogenic niches where physiologic apoptosis occurs to dispose superfluous 
progenitor cells that fail to mature (Biebl et al., 2000). Non-Tg wt mice, 
Tg(SHaPrP), Tg(SHaPrP, KH®II) mice all displayed similar and significantly 
higher apoptosis in the SVZ and SE compared to mice which do not express 
CtmPrP as Tg(SHaPrP, DSTE) and Prnp-/- mice, suggesting CtmPrP may have a 
role triggering apoptosis in this physiological disposal process. It is surprising that 
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Tg(SHaPrP, KH®II) mice did not show more apoptosis than wt expressers. It 
could be speculated that those cells undergoing physiologic apoptosis are 
accustomed to the expression of CtmPrP and are able to regulate it therefore no 
additional effect by increased CtmPrP expression is observed. Consistent with the 
data presented here it has been reported that PrPC can stimulate neurogenesis 
and leads to an increase in the progenitor population of the SVZ it wt mice in 
contrast to Prnp-/-  mice (Steele et al., 2006). Hence it is plausible that more 
excessive progenitors would need to be encountered by increased apoptosis as 
is seen here in this study, since no gross difference in the number of neurons or 
brain morphology is observed in Prnp-/- relative to wt mice (Bueler et al., 1992; 
Manson et al., 1994, Steele et al., 2006). Taken together, the data suggest that 
CtmPrP may play a role in regulating physiologic apoptosis in the SVZ and SE 
however under certain circumstances i.e. mutations in the STE and TM domains 
or infection with PrPSc can lead to pleiotropic expression of CtmPrP which can 
cause neurodegeneration.   
 
5.5 SecPrP protects cells from ROS-mediated cell death 
A neuroprotective role of PrP C against oxidative stress has been suggested 
(Wong et al., 2001; Brown et al., 2002). Yet it remained unclear if this is specific 
to the SecPrP isoform. In this study, a protective role for SecPrP was identified in 
CHO-KI cells, primary neuronal cultures and in transgenic mice. In all three 
model systems the DSTE mutant, which causes PrPC to be almost exclusively 
made in the SecPrP form, revealed the greatest protection to ROS, suggesting 
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that SecPrP protects from oxidative insult and that the reduced protective capacity 
in wt PrP expressing cells, neurons or non-Tg wt mice emerges as a result of the 
increased CtmPrP expression. Additionally,  the cell culture model system shows 
that PrPC can also display a protective function mediated by SecPrP in the same 
cell type from the pro-apoptotic one provided by CtmPrP. 
 
5.6 Gain and loss of PrPC mediated functions in non-Tg wt mice 
A functional contribution of CtmPrP and SecPrP was identified in a model system 
for KA-mediated neurodegeneration. Clearly mice favoring SecPrP expression 
revealed the greatest protection to the KA challenge in both terms of mortality 
and cell death in the pyramidal CA3 layer. The data indicates that this protection 
may arise from anti-oxidant properties of SecPrP which abrogates cell death and 
concomitantly averts organismal mortality. In contrast, expression of CtmPrP 
revealed to be most detrimental in response to KA with the highest mortality and 
the most dramatic apoptosis. The comparison of CtmPrP favoring mice and Prnp-/- 
mice suggests the additional cell death in CtmPrP favoring mice is distinct from the 
loss of SecPrP protection mediated cell death which appears to result from an 
increase in ROS. Therefore, the data can be interpreted to conclude that both 
topological isoforms of PrPC may contribute to KA-mediated vulnerability: CtmPrP 
triggers ROS independent apoptosis whereas SecPrP protects from ROS 
dependent apoptosis. A decrease of SecPrP expression and an increase in CtmPrP 
expression are likely independent effects that can work in concert to contribute to 
KA-induced vulnerability suggesting that both a gain of CtmPrP and loss of SecPrP 
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can lead to neurodegeneration. It is conceivable that differences in relative and 
absolute levels of SecPrP and CtmPrP may not be the only means to trigger 
independent pro- and anti-apoptotic functions of CtmPrP and SecPrP respectively 
but potentially also counteract the function of one another directly contributing to 
the overall outcome of cell death or cell survival which can not be readily 
discerned form the direct effect of each isoform in this model system.    
Non-Tg wt mice recapitulated the activities of both isoforms as seen in regard to 
its capacity to trigger apoptosis and in regard to the protection from oxidative 
stress. Therefore it can be reasoned that the reduced neuroprotection of non-Tg 
wt mice likely results from both the reduced propensity of PrPC to form SecPrP and 
its increased propensity to form CtmPrP relative to Tg(SHaPrP, DSTE) mice 
providing functional evidence that PrPC displays SecPrP-dependent and CtmPrP-
dependent functions in vivo. 
 
5.7 Gain of CtmPrP function and loss of SecPrP function in transmissible 
prion disease 
Finally, the data presented here suggests that both SecPrP and CtmPrP contribute 
to neurodegeneration in prion disease by loss- or gain-of-functions, respectively. 
To dissect the contribution of each PrP C isoform in prion disease, mice favoring 
expression of either the CtmPrP or SecPrP isoform were inocula ted with PrPSc; both 
groups developed neurodegeneration, although at different time points and with 
different pathologic changes in their brains. The data suggest that 
Tg(SHaPrP,A117V) mice succumbed to both apoptosis as a result of CtmPrP 
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upregulation and oxidative stress-mediated neurodegeneration as a result of 
SecPrP conversion to PrPSc. Conversely, the much-delayed pathogenesis in 
Tg(SHaPrP,DSTE) mice appeared to result from the increased oxidative damage 
due to the loss of SecPrP function. In conclusion, a model can be derived from the 
given data: The SecPrP-to-PrPSc conversion leads to a loss of the neuroprotective 
function of SecPrP resulting in a higher susceptibility of infected cells to ROS. 
Additionally, PrPSc accumulation leads to upregulation of CtmPrP, which triggers 
apoptosis (Summarized in Figure 18). Therefore, pathophysiology of infectious 
prion disease is possibly facilitated by both the apoptotic effects of CtmPrP and 
the loss of the protective effects of SecPrP. These findings provide context for 
various studies that have proposed different mechanisms for PrPC-mediated 
neurodegeneration including apoptosis and oxidative damage, and reconcile how 
both gain and loss (Brown, 2005; Harris & True, 2006) of PrPC functions may 
occur in prion disease. Since the detection of CtmPrP and PrPSc both relies on 
proteolysis new methods of detection for CtmPrP will need to be developed to 
establish a direct relationship of CtmPrP induction to transmissible prion disease 
like conformation specific antibodies that unmistakably identify the different 
isoforms of PrP without the need for proteolysis hence permitting in situ detection 
of CtmPrP which would make it possible to probe in various disease model 
systems if in PrPSc affected brain regions CtmPrP is induced. Furthermore, such a 
reagent would help to delineate the physiological role of CtmPrP in the SVZ and 
SE. 






Legend Figure 18. Model of PrPC-mediated pathogenesis in transmissible prion 
disease . Shown is the default secretory pathway (dashed lines). PrPC is cotranslationally 
synthesized at the ER as either SecPrP (blue) or CtmPrP (red), which is shuttled to the Golgi 
where further N-glycan maturation occurs, then delivered to the plasma membrane by 
endosomal vesicles (Gu et al., 2006). During infection with PrPSc (green), conversion of SecPrP 
to PrPSc occurs (1) on the plasma membrane, exosomes or lysosomes (Vey et al., 1996; 
Fevrier et al., 2005). This conversion leads to a loss of neuroprotective function of SecPrP to 
oxidative stress (2), resulting in cell dysfunction or death without DNA -fragmentation. 
Additionally, an accumulation of PrPSc leads to upregulation of CtmPrP (3, Hegde et al., 1999) 
resulting in increased apoptosis (4).  
 
Figure 18 
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5.8 Bifunctional physiological roles for PrPC 
In this study, multiple lines of evidence converged to set forth the hypothesis 
PrPC consists of two topological isoforms with independent functional roles: First, 
both SecPrP and CtmPrP were detected in brains of non-Tg wt mice. Second, both 
isoforms showed an equal degree of N-glycan maturation. Third, the propensity 
of wt PrPC to express CtmPrP correlated with its capacity to trigger apoptosis. 
Fourth, a putative physiological role for CtmPrP mediated apoptosis was identified 
in the SVZ and SE of non-Tg wt mice. Fifth, the capacity of PrPC to protect from 
ROS was dependant on the expression of SecPrP. Sixth, both functional 
contributions of SecPrP and CtmPrP were observed under acute excitotoxic and 
oxidative stress conditions in non-Tg wt mice. Seventh, the analysis of the 
pathophysiologic mechanisms underlying infectious disease revealed both gain 
and loss of PrPC-mediated functions identifying an engagement of both isoforms 
in the pathogenesis process, all supportive of the hypothesis that PrPC naturally 
consists of both CtmPrP and SecPrP with pro- and anti-apoptotic functions, 
respectively and reconcile how PrP C can be both protective and toxic (Brown, 
2005; Harris & True, 2006). 
 
5.9 Proposed novelties of this study 
In this thesis several advances could be made: 
First, previous studies have suggested that PrPC is solely expressed as SecPrP in 
brains of wild type mice (Hegde et al., 1998a; Stewart et al., 2005) and that 
CtmPrP is only expressed under pathological conditions (Hegde et al., 1998a; 
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Hegde et al., 1999; Stewart et al., 2005). In this study data is provided that shows 
under physiological conditions in addition to the SecPrP isoform, PrPC is also 
expressed as CtmPrP albeit at extremely low levels, suggesting PrPC can naturally 
be expressed as both SecPrP and CtmPrP. 
Second, the expression of CtmPrP has been previously linked to the onset of 
neurodegeneration in both genetic and transmissible prion diseases (Hegde et 
al., 1998a; Hegde et al., 1999; Stewart et al., 2005). Yet the mechanism by which 
CtmPrP could trigger disease remained unclear. An indication was provided by 
previous studies revealing that apoptosis may play a role in the manifestation of 
prion diseases (Giese et al., 1995; Liberski et al., 2004). The data in this study 
suggest that pleiotropic expression of CtmPrP causes neurodegeneration by 
activating an apoptotic pathway in a dose dependant manner. Furthermore, the 
data demonstrate that CtmPrP mediated apoptosis is likely executed by pro-
apoptotic molecules Bax and caspase-3 and abrogated by anti-apoptotic Bcl-2. 
Third, a previous study revealed that PrPC may stimulate neurogenesis (Steele et 
al., 2006) however it remained unclear why an increase in neuronal numbers or 
changes in brain morphology are lacking (Bueler et al., 1992; Manson et al., 
1994, Steele et al., 2006). A potential explanation for this phenomenon was 
provided by observations made in this study which revealed that a lack of CtmPrP 
expression results in reduced apoptosis in neurogenic brain regions of the SVZ 
and SE. Extrapolation of the aforementioned findings suggests CtmPrP may 
regulate the number of progenitor cells by triggering apoptosis establishing a 
potential physiologic role for CtmPrP. 
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Fourth, both neurotoxic  (Westaway et al., 1994; Shmerling et al., 1998; Paitel et 
al., 2003) and neuroprotective (Bounhar et al., 2001; Chiarini et al., 2002; 
Roucou et al., 2004) functions have been proposed for PrP C however it has 
remained unresolved by which mechanism these diametrically opposed functions 
may unfold. In this study it was demonstrated that functional manifestation of 
PrPC is dependent on the expression of the topological isoform of PrPC. A 
neuroprotective function against oxidative stress was attributed to the expression 
of SecPrP whereas a neurotoxic function triggering apoptosis was identified under 
conditions that favor the expression of CtmPrP.   
Fifth, it has previously been reported that PrPC exhibits neuroprotective and anti-
oxidant activity (Bounhar et al., 2001; Brown et al., 1997; Wong et al., 2001). In 
this study it could be demonstrated that the neuroprotective activity of PrP C is 
attributed specifically to SecPrP isoform both in vitro an in vivo. Furthermore, it 
was demonstrated that not only does SecPrP reduce the oxidative burden to 
pyramidal neurons of the hippocampus but can also avert organismal mortality. 
Sixth, It is becoming increasingly clear that PrP C plays a central role in the 
pathogenesis of transmissible prion disease (Chesebro et al., 2005) however it 
has been subject of debate whether this occurs through a gain of toxic function  
as has been proposed for CtmPrP or a loss of protective function associated with 
PrPC (Brown, 2005; LeBlanc & Roucou, 2003; Harris & True, 2006). Previous 
studies have revealed that apoptosis (Giese et al., 1995; Liberski et al., 2004) 
and oxidative damage (Milhavet et al., 2000; Wong et al., 2001; Brown, 2005) 
may both occur during prion disease. Evidence presented here in this study 
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reveals that upregulation of CtmPrP which has been demonstrated previously 
(Hegde et al., 1999), correlates with abbreviated onset of disease and as shown 
here is accompanied by increased apoptosis and oxidative damage in brain 
areas with PrPSc accumulation. Conversion of SecPrP to PrPSc and its concomitant 
loss of activity lead to a higher susceptibility to oxidative stress, albeit it appears 
that the loss of SecPrP function is not as strong a determinant of the pathogenesis 
process as the upregulation of CtmPrP associated gain of apoptotic activity. Taken 
together, the data presented here provide a basis reconciling how both gain and 
loss of PrPC functions may occur in transmissible prion disease. 
 
5.10 The world of PrPC heterogeneity 
The heterogeneity of PrP C extends beyond the topological isoforms described 
and characterized here in this study. Glycosylation variants (Pan et al., 2002)., 
truncated forms (Vincent et al., 2000), a soluble form lacking the GPI anchor 
(Perini et al., 1996) and a cytoplasmic form have been also described. 
Cytoplasmic PrP can cause cell death and neurodegeneration (Ma et al., 2002) 
however a protective role against Bax-mediated apoptosis has also been 
described (Roucou et al., 2003). A role in natural prion disease remains to be 
described while studies in wt mice suggests that it may naturally occur in neurons 
(Mironov et al., 2003). The formation of cytoplasmic PrP has been linked to both 
retrotranslocation of PrP from the ER (Wang et al., 2005) and leaky ribosome 
scanning (Kang et al., 2006). The notion that it has the BH2 like OR domain also 
exposed in the cytoplasm makes it like CtmPrP a candidate interacting partner 
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with the BH2 family proteins. It will be most interesting to see if cytoplasmic PrP 
also plays a role in any form of prion disease and if and what type of 
physiological role it may exhibit. 
Recently, it has also been proposed that integrase dependent proteolytic 
cleavage of PrPC can produce the C1 truncated form of PrPC that can also trigger 
apoptosis (Sunyach et al., 2007). The data in this study do not reveal any toxic 
activity associated with C1, since the DSTE mutant produces abundant C1 yet 
lacks any sign of toxicity. Hence future investigation will be required to identify 
this discrepancy. 
Furthermore, over 50 different glycosylation variants have been described for 
PrPC (Pan et al., 2002). Whether a specific physiological and pathological role 
can be attributed to these forms remains unanswered. Also clarification of a 
potential role for NtmPrP awaits future studies. 
Finally, it should be noted that despite strong evidence presented here in this 
study it can not be ruled out if other variants of PrPC that escaped detection by 
the methods employed here in this study which may also contribute to one or 
several of the here made observations. It is conceivable that conditions that favor 
the formation of CtmPrP could potentially also favor the generation of a yet 
another form of PrPC which is actually toxic and CtmPrP only an innocent 
bystander which may equally apply to the role proposed for SecPrP. Certainly 
future studies will shed light on this question and it will be interesting to see what 
roles all these different forms may ultimately have. 
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5.11 Protein heterogeneity: A new paradigm? 
The focus of this study was to demonstrate the potential of PrP C to be expressed 
in two topological forms that partake in independent functions.  PrPC may 
represent a novel class of proteins that are potentially bifunctional, but as far as 
is known, can have their function changed only by a change in de novo 
synthesis. Thus, the term PrPC is ambiguous, as it does not specify which 
topological isoform is being referred to, a description of which can change either 
spatially or temporally, in processes that can be either physiological or 
pathological, in which PrPC is involved. It is important to note that conventional 
proteomic analysis measuring simply the level of PrPC expression would have 
missed the occurrence of multiple PrPC topological isoforms. It is possible that 
proteins other than PrPC display multi-functionality due to isoforms different in 
conformation but not topology, therefore making them even more difficult to 
detect. Therefore the question emerges whether this level of heterogeneity may 
be applied more universally to other mammalian or eukaryotic proteins  has 
emerged to further increase the output of the genome. Therefore, it will be most 
interesting to see whether the “one gene-one protein” hypothesis will hold to the 
scrutiny of future experimentation. 
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6. Summary 
The physiological function of the cellular prion protein (PrPC) and its contribution 
to prion diseases remains enigmatic as evidence suggests both pro- and anti-
apoptotic functions. The data presented here suggest PrPC is expressed in two 
topological isoforms with unique functional manifestations and with the 
participation of both in the pathogenesis of prion disease. Expression of two 
topological isoforms were identified in wild type mice, a fully secreted isoform, 
designated SecPrP and a small fraction as a single spanning transmembrane 
isoform designated CtmPrP. By introducing mutations that favor expression in 
either SecPrP or CtmPrP the functional role of each form was dissected. Transgenic 
mice that favor CtmPrP expression develop spontaneous neurodegeneration with 
evidence of apoptotic cell death. Further investigation in cultured mammalian 
cells identified a Bax and caspase-3 dependant pathway by which CtmPrP triggers 
apoptosis in a dose dependant manner. In contrast, SecPrP reveals a protective 
role against apoptosis as seen in the hippocampus of transgenic mice challenged 
with kainic acid which otherwise leads to dramatic cell death by increased 
oxidative stress. The observation was made that CtmPrP favoring mice are most 
vulnerable to kainic acid mediated neurodegeneration where as SecPrP favoring 
mice are the least vulnerable to the same treatment. The protective role of SecPrP 
against oxidative stress was confirmed in cultured mammalian cells and primary 
cultured neurons. Finally, the contribution of each isoform was assessed in mice 
inoculated with prions (PrPSc). Mice favoring expression in the CtmPrP form 
developed symptoms at ~50 days and showed focal accumulation of PrPSc and 
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neurodegeneration proximal to the inoculation site with indications of both 
apoptotic and oxidative stress related degeneration. Mice favoring expression in 
the SecPrP form develop symptoms at ~320 days with accumulation of PrPSc 
throughout the brain yet only show signs of oxidative stress related damage. 
In conclusion, evidence is provided that wild type PrPC has the intrinsic capacity 
to be expressed as either SecPrP or CtmPrP and that each isoform can partake in 
independent pathways. SecPrP participates in a neuroprotective pathway against 
oxidative stress whereas CtmPrP activates a caspase-3 dependant apoptotic 
pathway. Further evidence suggests that both isoforms participate in the etiology 
of infectious prion disease: upregulation of CtmPrP which leads to apoptosis and 
conversion of SecPrP to PrPSc and its down regulation lead to a higher 
susceptibility to oxidative stress, thus being able to reconcile how both gain and 
loss of PrPC functions may occur. 
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7. Zusammenfassung 
Prionen sind infektiöse Eiweisse, die fatale neurodegenerative Erkrankungen in 
Säugetieren hervorrufen können. Es wird angenommen, dass die pathologische 
Isoform das sogenannte PrPSc die Umfaltung der zellulären Isoform des Prion-
Proteins (PrPC) in weitere krankheitserregnde PrPSc katalysiert. Es gibt jedoch 
Indizien die darauf hindeuten, dass PrPC an der Erkrankung beteiligt ist und das 
PrPSc nicht unmittelbar zur Neurodegeneration beiträgt. Ein Modell des 
zellbiologischen Krankheitsverlaufs geht davon aus, dass PrPC toxische Aktiviät 
besitzt, ein anderes Modell geht davon aus, dass der Verlusst von PrPC und 
seiner neuroprotektiven Aktivität für die Symptome verantwortlich ist. Die 
Entdeckung zweier unterschiedlicher isoformen von PrPC könnte nun beide 
Modelle vereinen. In vitro Analyse der PrPC-Synthese zeigt, dass PrPC in drei 
topologische Isoformen synthetisiert werden kann. Zwei dieser Isoformen 
durchspannen die Zellmembran in entgegengesetzter Orientierung, eine mit dem 
C-terminus (CtmPrP), die andere mit dem N-terminus (NtmPrP) im Zytoplasma.und 
die dritte Form ist ein sekretiertes Protein (SecPrP). 
In der vorliegenden Arbeit wird untersucht, ob die Funktion von PrPC von seiner 
Faltung abhaengt. Zuerst konnte gezeigt werden, dass unter physiologischen 
Bedingungen sowohl SecPrP als auch CtmPrP in vivo exprimiert werden. Um 
Erkentnisse über die Funktion der jeweiligen Isoform zu erhalten wurden 
Mausmodelle und Zellkultumodelle untersucht, die bevorzugt jeweils SecPrP oder 
CtmPrP expremieren. Mit Hilfe dieser Modelle konnte ich eine pro-apoptotische 
Aktivität von CtmPrP  nachweisen, die sich unter Mitwirkung der Proteine Bax und 
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Caspase-3 vollzieht. Ich konnte auch zeigen, dass die Proteine Bcl-2 und Bcl-XL 
der apoptotischen Aktiviät von CtmPrP entgegen wirken können. Darueberhinaus 
zeigte sich, dass ohne CtmPrP eine verringerte Apoptose in Gehirnregionen mit 
Neurogenese vorliegt. Deshalb liegt die Vermutung nahe, dass CtmPrP die 
Entstehung neuronaler Vorläuferzellen regelt. Im Gegensatz zu CtmPrP  zeichnet 
sich SecPrP durch eine neuroprotektive Funktion aus, die vor oxidativer 
Schädigung schützt. Die Isoform SecPrP schützt Pyramidal-Zellen des 
Hippokampus vor Apoptose die durch erhöhte oxidative Schädigung 
hervorgerufen wird. Die Daten lassen die Schlussfolgerung zu, dass sowohl 
CtmPrP als auch SecPrP physiologische Funktionen besitzen. 
Pathophysiologisch manifestieren sich diese zellbiologischen Prozesse wie folgt: 
Mäuse die hauptsächlich CtmPrP exprimieren erkranken wesentlich schneller, 
wiesen weniger PrPSc auf, und zeigten sowohl apoptotische als auch oxidative 
Neurodegeneration. Hingegen erkranken Mäuse, die hauptsächlich SecPrP 
exprimieren wesentlich später, trotz weit verbreiteter PrPSc Akkumulation und 
ohne Anzeichen für Apoptose. Die Daten lassen die Schlussfolgerung zu, dass in 
infektiösen Prionen-Erkrankungen CtmPrP die Apoptose einleitet, und das SecPrP 
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